Review

Bioactive Compounds and Metabolites from Grapes and Red Wine in Breast Cancer Chemoprevention and Therapy

Danielly C. Ferraz da Costa 1, Luciana Pereira Rangel 2, Julia Quarti 3, Ronimara A. Santos 1, Jerson L. Silva 4,* and Eliane Fialho 3,*

1 Departamento de Nutrição Básica e Experimental, Instituto de Nutrição, Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20550-013, Brazil; daniellyferraz@ymail.com (D.C.F.d.C.); ronimaras@gmail.com (R.A.S.)
2 Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil; lprangel@pharma.ufrj.br
3 Departamento de Nutrição Básica e Experimental, Instituto de Nutrição Josué de Castro, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil; julia.quarti@hotmail.com
4 Programa de Biologia Estrutural, Instituto de Bioquímica Médica Leopoldo de Meis, Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil

* Correspondences: jerson@bioqmed.ufrj.br (J.L.S.); fialho@nutricao.ufrj.br (E.F.);
Tel.: +55-21-3938-6756 (J.L.S.); +55-21-3938-6799 (E.F.)

Academic Editors: José Antonio Lupiáñez, Amalia Pérez-Jiménez, Eva E. Rufino-Palomares and Luca Rolle

Received: 15 May 2020; Accepted: 28 July 2020; Published: 1 August 2020

Abstract: Phytochemicals and their metabolites are not considered essential nutrients in humans, although an increasing number of well-conducted studies are linking their higher intake with a lower incidence of non-communicable diseases, including cancer. This review summarizes the current findings concerning the molecular mechanisms of bioactive compounds from grapes and red wine and their metabolites on breast cancer—the most commonly occurring cancer in women—chemoprevention and treatment. Flavonoid compounds like flavonols, monomeric catechins, proanthocyanidins, anthocyanins, anthocyanidins and non-flavonoid phenolic compounds, such as resveratrol, as well as their metabolites, are discussed with respect to structure and metabolism/bioavailability. In addition, a broad discussion regarding in vitro, in vivo and clinical trials about the chemoprevention and therapy using these molecules is presented.

Keywords: bioactive compounds; metabolites; wine; grapes; breast cancer; chemoprevention; chemotherapy

1. Introduction

Breast cancer was ranked as the fifth leading cause of death (627,000 deaths, 6.6%) worldwide in 2018 [1]. During the last decade, new strategies based on the use of dietary chemopreventive agents for breast cancer management have been developed. Several in vitro and in vivo studies have reported the beneficial effects promoted by bioactive compounds from grapes and its derivative products [2]. The positive impact on health has been attributed to its phenolic compounds, such as flavonoids, stilbenes, anthocyanins and other molecules. This review aims to summarize the current findings regarding the role of bioactive compounds from grapes and red wine and their metabolites on breast cancer chemoprevention and treatment by exploring its molecular targets and mechanisms of action [3].

In cancer research, a wide variety of established breast cancer cell lines are used as experimental models. Most of them resemble the different subtypes of breast cancer seen in the clinic. These cell lines
offer an infinite supply of a relatively homogeneous cell population that is capable of self-replication in standard cell culture medium and are available through commercial cell banks. The most commonly used breast cancer cell line in the world, MCF-7, was established in 1973 at the Michigan Cancer Foundation. With different molecular characteristics, MDA-MB-231, MDA-MB-453, MDA-MB-468, TD47D, among others, are frequently used in studies, as will be described below [4].

2. Anticancer Effects Produced by Grapes and Seed Extracts

Grapes and their derivative products are a rich source of bioactive molecules, including flavonoid compounds (flavonols, monomeric catechins, proanthocyanidins, anthocyanins, anthocyanidins) and non-flavonoid phenolic compounds (resveratrol), as well as their metabolites. Several molecular pathways involved in breast cancer cell signaling and differentiation, cell cycle arrest, apoptosis, and metastasis can be modulated by these compounds, as described below (Figure 1).

![Figure 1](image)

**Figure 1.** Anticancer activities promoted by phenolic compounds from grapes and red wine and their metabolites.

A polyphenolic fraction isolated from grape seeds (GSP) containing 50% of procyanidins, 5% of catechin and 6% of epicatechin that has been described to cause irreversible inhibition growth of MDA-MB-468, a metastatic breast cancer cell line, by a mechanism involving activation of MAPK/ERK1/2 and MAPK/p38, the two MAPK pathways associated with cell growth and differentiation. GSP also promoted the induction of CDKI Cip1/p21 and a decrease in CDK4, resulting in G1 arrest [5]. Polyphenols obtained by hydroalcoholic extraction from grape seeds promoted a selective inhibition of cell viability and induction of apoptotic cell death on MCF-7 cells. The authors hypothesize that this effect is mediated by gap-junction-mediated cell-cell communications improvement via re-localization of Cx43 proteins and up-regulation of CX43 gene, since gap junctions have been associated with the apoptotic process [6].

Extracellular matrix remodeling, which is influenced by urokinase-type plasminogen activator (uPA) and matrix metalloproteinases (MMPs), is a critical event in the metastasizing process.
Dinicola et al. [7] have studied the effect of grape seed extract (GSE) containing 6.2 mg/g of catechins and 5.6 mg/g of procyanidins on metastatic human breast carcinoma cell line focusing on migration and invasion processes. Low GSE concentrations (25 µg/mL) were reported to strongly inhibit MDA-MB-231 cell migration and invasion by decreasing uPA, MMP-2 and MMP-9 activity, as well as down-regulating β-catenin, fascin and NF-κB expression. On the other hand, high GSE concentration (50 and 100 µg/mL) triggered proliferation arrest and apoptosis.

Another target in the treatment of several cancers is the inhibition of angiogenesis, which is supported by vascular endothelial growth factor (VEGF). A study by Lu et al. [8] showed that GSE (85% procyanidins) reduced VEGF expression in both U251 human glioma cells and MDA-MB-231 human breast cancer cells, supporting the hypothesis that GSE may be a natural anti-angiogenesis source of compounds.

Previous studies described many phytochemicals found in grapes and wine as aromatase inhibitors [9]. Polyphenols were demonstrated to modulate estrogen signaling and to compete for steroid-binding sites. Kijima et al. [10] reported that GSP (74–78% proanthocyanidins and <6% catechin, epicatechin, and their gallic acid esters) suppressed aromatase expression and activity on MCF-7aro (aromatase transfected MCF-7 cells) and SK-BR-3 cells. Aromatase catalyzes critical reactions of estrogen synthesis, converting androsterone to estrogen, which is known to stimulate breast cancer cell growth by binding to the estrogen receptor (ER). Another approach includes the combination of therapeutic compounds, like doxorubicin (Dox), and phytochemicals for cancer management. GSE (95% procyanidins) increases the efficacy of Dox in human breast cancer MCF-7, MDA-MB468, and MDA-MB231 cells suggesting a strong possibility of a synergistic effect of GSE and Dox combination, independent of the estrogen receptor status of cells [11].

Grape seed proanthocyanidin extract (GSPE) showed also a promising therapeutic role against adverse effects of the chemotherapeutic agents carboplatin and thalidomide. Administration of these agents in rats led to an enhancement in the TNF-α and IL-6 cytokine levels, which could be partially reversed by administration of GSPE. In addition, GSPE reduced free radicals like thiobarbituric acid-reactive substances and nitric oxide and increased glutathione and antioxidant enzymes in liver and heart [12].

3. Flavonoid Compounds

3.1. Flavonols

Flavonols are a subgroup of the flavonoids group, structurally resembling flavones, with the presence of an additional hydroxyl in position 3 of the A ring of the flavones general backbone (3-hydroxyflavone) (Figure 2). The most abundant flavonols present in wine are quercetin, a majoritary compound in this beverage, kaempferol, myricetin, isorhamnetin (quercetin 3′-methylether), and rutin, a glucoside derivative of quercetin [13].

![Figure 2. (a) Basic structure of flavonols. (b) Kaempferol. (c) Quercetin.](image)

In red wine, flavonol (aglycones and glycosides) concentration ranges from around 3 to 50 mg/L [14,15], while quercetin varies from around 1 to 10 mg/L in different wines from different regions of the world [16,17].
Flavonol concentration appears to be related to the degree of sun exposure of the grapes while cultivated and the degradation is both related to UV exposure and temperature [13,18]. Moreover, flavonol content is dramatically altered during the processing of grapes, wine production, and storage [13,19,20].

Flavonol bioavailability may vary according to the substitutions found in the molecule, e.g., sugars (mostly glycosides). A relevant example is rutin, a glycosidic disaccharide conjugate of quercetin [13]. The glycosylated forms are the most frequently found in wine and these compounds appear to be more resistant to degradation than their correspondent aglycones [21].

We discuss below the particular effects of quercetin and kaempferol, the most abundant flavonols in wine, on breast cancer. Their effects encompass both chemoprevention and therapy. Although their aglycone forms share a high structural resemblance, the targets, mechanisms of action and bioavailability of these compounds may vary according to the metabolites produced and substitutions found [22,23].

The anticancer effects of kaempferol and quercetin have been described in several different cancer types, such as bladder, breast, prostate, ovarian, liver, and colon. A special feature is given to breast cancer due to a superior number of published works. The few epidemiological studies available using flavonoids such as quercetin or kaempferol on breast cancer involve the observation of their dietary contribution. However, their findings vary from null to positive effects in cancer prevention [24–26]. It is important to mention that, in spite of the larger number of basic research papers published so far, there is a small number of preclinical and clinical studies using kaempferol or quercetin as anticancer agents [27,28]. This is due to their low bioavailability, which is around 2% for kaempferol [29,30] and 20% for quercetin, while only 1% was found in the free form in serum [31,32]. This has inspired several works describing drug delivery systems including quercetin and other drugs, such as doxorubicin [33–35]. Likewise, the blending of kaempferol and other flavonoids, either in a complex mixture [36] or simply in combination with quercetin, has been described to increase their anticancer properties [37].

In a general way, the anticancer activities of these two flavonols in breast cancer can be organized in three groups: apoptosis induction, growth inhibition (cell cycle arrest), and inhibition of the metastatic behavior: invasion, migration and epithelial-mesenchymal transition (EMT). Several different papers describe the effects of kaempferol and quercetin in the induction of apoptosis in breast cancer cells, such as MCF-7, MDA-MB-453, SK-BR-3, and MDA-MB-231 [38–40]. Kaempferol and quercetin decrease the growth of MCF-7 and MDA-MB-231 cells with micromolar concentrations. However, the MCF-7 cell line appeared to be more sensitive to quercetin than MDA-MB-231 [41–44]. The same was observed for kaempferol in an MCF-7 3-D model, with ERK signaling being responsible for the apoptotic death [45] and cell cycle arrest at the sub-G1 phase [40].

Kaempferol was found to inhibit the RhoA and RacA signaling pathways, leading to cell migration and invasion inhibition in MDA-MB-231 and MDA-MB-453, triple negative breast cancer (TNBC) cells [41]. This compound was also found to promote PARP cleavage for apoptosis induction through the downregulation of Bcl-2 and BAX induction [38]. On the other hand, kaempferol demonstrated a strong antioxidant activity that was able to attenuate ROS-induced hemolysis and to promote an antiproliferative effect on different tumor cell lines, including MCF-7 cells [46].

Quercetin has been widely reported for its activity against breast cancer cell lines such as MCF-7 and MDA-MB-231 [47–49]. The mechanisms of action involved apoptosis induction through different pathways, such as caspase activation through the mitochondrial pathway [50,51], inhibition of the Akt signaling pathways [52,53], and cell cycle arrest in the G2/M phase [39,44,50,54]. These effects have been shown in vitro, but also in vivo [22]. Quercetin induces necroptosis, with an increase in BAX expression and Bcl-2 inhibition [55]. In combination with chloramphenicol, isorhamnetin, the main metabolite of quercetin in mammals, was shown to induce mitochondrial fission through CaMKII/Drp1, leading to apoptosis [56]. Also, quercetin-3-O-d-galactopyranoside induced apoptosis via ROS through the inhibition of NFκB signaling pathway and activation of the BAX-caspase 3 axis [57]. Dietary quercetin has demonstrated an inverted “U”-shaped dose-dependent curve on the C3(1)/SV40 Tag breast cancer mouse model [58].
The antimetastatic potential of these compounds involves their ability to inhibit the expression of metalloproteinases such as MMP-3 and MMP-9 [53,59,60]. EMT and angiogenesis in breast cancer cells are also inhibited by quercetin [61,62].

Fatty acid synthase inhibition by flavonoids has been reported and associated with modulation of cell growth and promotion of apoptosis [63]. Quercetin led MDA-MB-231 and MCF-7 cells to EGFR reduction and this signaling promoted fatty acid alterations, including fatty acid isomerization and free radicals production [64].

The structure similarity of estradiol and flavones confers on them a potential to interfere in tumor growth and development through the interaction with ERs [65–68] and aromatase [69,70]. Preliminary reports show an anti-estrogenic activity for quercetin [71,72], but kaempferol stood out in a panel of phytoestrogens as the one with the most affinity with ERα, which enhances estrogen-dependent cell proliferation [68], displaying estrogenic affinity at 5 µM in a luciferase model in MCF-7 cells. Also, in this cell line, kaempferol revealed a dual effect, according to the concentration used: at the 10 µM range, it was described as an ER competitor with estrogen, since the increase in estrogen concentration was able to impair its functions. On the other hand, at a higher concentration of kaempferol, 100 µM, increments in estrogen concentration were unable to block the kaempferol effect, suggesting different pathways for activation by this compound [73].

In this sense, kaempferol is able to overcome the effects produced by triclosan and bisphenol A, exogenous xenoestrogenic compounds considered endocrine-disrupting chemicals (EDCs) with anti-apoptosis effects [74]. Kaempferol was shown to reverse these effects, increasing BAX levels and reducing Bcl-2 levels, leading VM7Luc4E2 cells to apoptosis [75]. Kaempferol was also able to suppress the EMT and metastatic-related behaviors of MCF-7 cells induced by triclosan [76] and to reverse triclosan-induced phosphorylation of IRS-1, AKT, MEK1/2 and ERK. In a 17β-estradiol (E2) or triclosan tumor growth-induced in vivo xenograft mouse model, co-treatment with kaempferol inhibited tumor growth [74].

Quercetin has been described as a multidrug resistance (MDR) inhibitor in several different works. It is defined as an inhibitor of p-glycoprotein by direct binding to this efflux pump, but also through the downregulation of p-gp expression [77–79]. Furthermore, quercetin was shown to potentiate the doxorubicin effect and to reduce its toxicity and side effects, both in vitro and in vivo [33,80]. Similar effects were seen with other drugs such as docetaxel [81], tamoxifen [82], paclitaxel and vincristine [79] using different drug delivery systems. Kaempferol is able to reverse drug resistance promoted by ABCG2 [83,84] and to inhibit quercetin efflux by this transporter [85].

Multidrug transporters are also acknowledged in the metabolism/elimination of quercetin and kaempferol. ABCG2 and ABCC2 participate in kaempferol-3-glucuronide (the major metabolite of kaempferol) elimination in vivo [86]. Finally, the cooperation between ABC transporters and UDP-glucuronosyltransferases appears to regulate kaempferol glucuronidation, thus regulating its accumulation in cells (in comparison to the glucuronide forms) with effects on the pharmacological properties of this compound [87].

3.2. Monomeric Catechins and Proanthocyanidins

Catechins, epicatechins, and proanthocyanidins are naturally occurring flavan-3-ols, typically found in tea, cocoa, grape, and wine [88]. Proanthocyanidins are the major phenolic compounds in grape seed and skin [89] and catechins are present in large amounts in green and black teas [90] and in red wine [91]. Proanthocyanidins, also known as condensed tannins, are phenolic compounds that take the form of dimers, trimers, and highly polymerized oligomers of flavan-3-ol units [92,93]. Therefore, proanthocyanidins are metabolized to catechins and catechin derivatives [94].

Previous studies indicated that (+)-catechin and (−)-epicatechin (Figure 3) are rapidly absorbed from the upper portion of the small intestine in both human and animal organisms [95]. Catechin bioavailability is inversely proportional to its molecular masses. For example, although the (−)-epigallocatechin-3-gallate (EGCG) content in tea is much higher than other catechins, the peak
plasma levels for EGCG (458 Da), (−)-epigallocatechin (306 Da), and (−)-epicatechin (290 Da) are 0.26, 0.48, and 0.19 μM, respectively. Plasma (+)-catechin concentrations increased in response to the ingestion of a single serving of reconstituted red wine. A maximum level of (+)-catechin at 76.7 nmol/L was detected in humans at 1.4 h after intake of both dealcoholized and reconstituted wine [91]. The bioavailability of procyanidins closely resembles that of flavan-3-ol monomers. Different studies, following the ingestion of GSE and GSPE, have shown that during digestion, the oligomers are fragmented into monomeric units of (+)-catechin and (−)-epicatechin and free forms of dimers and trimers have been detected in rat plasma [96,97]. Procyanidin B1 was also detected in human serum 2 h after intake of GSE [98]. Biotransformation of catechins directly undergoes phase II of metabolism, where they can be methylated by catechol-O-methyltransferase (COMT), glucuronidated by UDP-glucuronosyltransferase (UGT) or sulfated by sulfotransferase (SULT) [99]. Catechins can also be degraded in the intestinal tract by microorganisms to ring fission metabolites M4, M6, and M6′ [100].

![Figure 3. Structures of (a) (+)-catechin and (b) (−)-epicatechin.](image)

The biological activities of these polyphenols that exert an effect on breast cancer were obtained from a variety of studies, including in vitro and in vivo data. Isolated catechin decreased cell viability and proliferation of MCF-7 human breast cancer cells at 30 and 60 μg/mL [101]. Alshatwi et al. [102] demonstrated that catechin hydrate (150 μg/mL and 300 μg/mL) effectively induced apoptosis in MCF-7 cells through increased expression levels of caspases -3, -8, -9 and p53.

Interestingly, inhibition of cell proliferation by purified (+)-catechin and (−)-epicatechin was more effective in hormone-sensitive breast cancer cells (MCF-7 and T47D), also demonstrating a possible implication of steroid hormone receptors in the action of polyphenols, and in fact, a competition of epicatechin for ER was reported [103].

The anti-carcinogenic activity of wine polyphenols is related to the protection of DNA damages by chemically reactive molecules, such as ROS (reactive oxygen species). The antioxidant effect of purified polyphenols was investigated in three types of breast cancer cells. The treatment with catechin and epicatechin decreased about 80% of ROS production on T47D cells, while no effect was noticed on MDA-MB-231 and MCF-7 cells. The authors attributed the results to different constitutive ROS production between cell lines, hormone receptor spectrum (considering interaction of ROS and these molecules) and limitations of the method [103].

The chemopreventive activity of GSE was demonstrated in an established carcinogen-induced animal model of breast cancer. Adult rats that received 5% GSE (86% proanthocyanidins) showed 44% reduction in the number of DMBA (7,12-dimethylbenz(a)anthracene)-induced mammary tumors [94]. The same effect was observed on a xenograft model using BALB/c nu/nu, athymic, ovariectomized mice carrying MCF-7aro tumors. Mice gavaged with GSE (74–78% proanthocyanidins and <6% catechin, epicatechin and their gallic acid esters) had a 70% reduction in tumor growth, indicating that GSE could suppress aromatase-positive tumors in vivo [10]. On the other hand, diets supplemented with 0.1%, 0.5% and 1.0% of grape seed proanthocyanidins (3.8% of catechin and epicatechin, 96.2% of oligomers and polymers) were not effective in reducing DMBA-induced rat mammary carcinogenesis. The authors attributed the results to the poor absorption of the components and, thus, insufficient amounts being available in the mammary gland to modulate tumorigenesis [104].
In humans, a pilot study with daily doses of grape GSPE failed to decrease plasma estrogens in postmenopausal women [105], despite the same extract exhibit inhibition in cell growth on MCF-7 cells in culture [106]. A double-blind placebo-controlled randomized phase II trial investigated the efficacy of IH636 GSPE in patients with tissue induration, considered a late adverse effect of curative radiotherapy for early breast cancer. In this study, 44 volunteers were given 100 mg of GSPE three times a day orally for six months. The authors considered that the study failed to demonstrate the efficacy of orally-administered GSPE, since there was no significant difference between the groups in terms of external assessments (tissue hardness, breast appearance) or patient self-assessments (breast hardness, pain or tenderness), 12 months post-randomization [107], although the same extract exhibited inhibition in cell growth of MCF-7 cells in culture at 25 mg/L [106].

Additionally, other health effects attributed to GSE and GSPE demonstrated potential to improve antioxidant cell defenses and modulate proinflammatory cytokines, which possibly complement the antitumoral functions of these matrices [108].

3.3. Anthocyanins and Anthocyanidins

Anthocyanins are the most abundant flavonoid pigments in young red wines, being responsible for their intense red color [109]. To date, the number of reported types of anthocyanins exceeds 600 [110], but the most common anthocyanidins, aglycone forms of anthocyanins, are cyanidin, pelargonidin, delphinidin, peonidin, petunidin, and malvidin [111] (Figure 4). Anthocyanidins could be immediately metabolized after ingestion of anthocyanins since the β-glucosidase found in intestinal bacteria can easily hydrolyze respective anthocyanins (glycosides) to anthocyanidins (aglycones) [112]. Anthocyanins are known for their apparent poor bioavailability (less to 1–2%). However, presystemic metabolism of these compounds may underestimate their bioavailability if only parent compounds and/or phenolic acid breakdown products are targeted in bioassays. Taking into account the original parent compounds, generated metabolites (from phase I and phase II metabolism and from microbiota-generated) and conjugated products, total bioavailability is much higher than previously credited, after all, anthocyanins are very influential to health [113].

![Figure 4. The most frequent anthocyanidins. (a) cyanidin, (b) pelargonidin, (c) delphinidin, (d) peonidin, (e) petunidin, (f) malvidin.](image-url)
autophagy modulation, anti-metastasis, reversion of drug resistance and increasing the sensitivity of cancer cells to chemotherapy [114].

The effects of anthocyanins on breast cancer are some of the most studied, both concerning prevention and treatment of this disease. One of the proposed mechanisms of carcinogenesis is the formation of carcinogen-DNA adducts in target tissues, which is essential to the initiation of chemically induced breast cancer [115]. Singletary et al. [116] evaluated an anthocyanin-rich extract from Concord grapes and the major anthocyanins detected in this extract, delphinidin aglycone and its glucoside, for their capacity to inhibit DNA adduct formation due to the environmental carcinogen benzo[a]pyrene (BP) in a noncancerous, immortalized human breast epithelial cell line (MCF-10F). These authors observed that both grape extract (10 and 20 µg/mL) and isolated compounds (0.6 µM) inhibited BP–DNA adduct formation, through enhancing phase II metabolizing enzymes (GST and NQO1) activities, and suppressed reactive metabolites such as ROS.

Syed et al. [117] also showed that delphinidin, the most common anthocyanidin monomer, could prevent tumor development and malignant progression through inhibition of breast oncogenesis. These authors also assessed experiments with the MCF-10A cell line, a non-tumorigenic mammary epithelial cell line for studying normal breast cell function and transformation, and demonstrated that delphinidin (5 to 40 µM) inhibited HGF-induced early biochemical effects, blocking proliferation and migration of this cell line.

Hepatocyte growth factor (HGF) is produced mainly by mesenchymal cells and acts primarily through its only receptor, c-Met [118]. A variety of cellular responses are activated by c-Met/HGF signaling and mediate critical physiological processes for tumor growth and metastasis in human cancers, including angiogenesis [119], cellular invasion [120–122], and morphogenic differentiation [123]. In addition to observing effects on non-tumor breast cells, Syed et al. [117] showed that delphinidin treatment caused growth inhibition of breast cancer cells that express HGF, suggesting that this compound could prevent HGF-mediated activation of signaling pathways implicated in breast cancer.

The chemopreventive effects of delphinidin-3-glucoside were also evaluated on breast carcinogenesis [124]. Yang et al. [124] described that this phytochemical effectively suppressed carcinogenic transformation of MCF-10A cells induced by carcinogen treatment (NNK and BP). After that, these authors investigated the molecular mechanism related to lncRNA HOTAIR transcript antisense RNA (HOTAIR) modulation. Long non-coding RNAs (lncRNA) are usually related to a group of RNAs with more than 200 nucleotides and are not involved in protein generation, despite being involved in different regulatory processes, such as modulation of gene expression [125]. HOTAIR, which is over-expressed in different types of cancers, is a lncRNA that plays a role in carcinogenesis and cancer progression by promoting cancer cell viability, growth, and metastasis [126]. In its turn, HOTAIR is regulated by the interferon regulatory factor-1 (IRF1) protein, which decreases HOTAIR expression. On the other hand, Akt activation decreases IRF1 expression and, consequently, elevates HOTAIR levels [127,128]. Yang et al. [124] observed that delphinidin-3-glucoside treatment (40 µM) inhibited HOTAIR expression in breast carcinogenesis and breast cancer cells. Besides that, these researchers also found the same results in xenografted breast tumors in athymic mice. Mechanistically, in this study delphinidin-3-glucoside down-regulates HOTAIR by inhibiting Akt activation and promoting IRF1.

The first report of tumor cell proliferation inhibitory activity of anthocyanidins from grape skin was published by Zhang et al. [129]. These authors tested the cell proliferation inhibitory activity of five anthocyanidins (cyanidin, delphinidin, pelargonidin, petunidin, and malvidin) and four anthocyanins (cyanidin-3-glucoside, cyanidin-3-galactoside, delphinidin-3-galactoside, and pelargonidin-3-galactoside) against diverse human cancer cell lines. Although anthocyanins did not inhibit proliferation of any cell line tested, even at the highest concentration (200 µg/mL), anthocyanidins inhibited cancer cell proliferation, with malvidin and pelargonidin being the most promising compounds, since they affected many different cancer cells at the same time.
Afaq et al. [130] evaluated the effect of delphinidin (5–40 µM) on epidermal growth factor receptor (EGFR)-positive breast cancer AU-565 cells and non-tumorigenic MCF-10A cells. EGFR is overexpressed in about 20% of invasive breast carcinoma [131] and has been implicated in tumor progression since it promotes a loss of balance between proliferation and apoptosis. The authors showed that this compound is an inhibitor of EGFR and its downstream signaling, the PI3K/AKT and MAPK pathways, both of which play a significant role in the mitogenic and cell survival responses mediated by EGFR. This same study also demonstrated that delphinidin treatment caused more dramatic inhibition of growth of AU-565 cells than MCF-10A cells and had minimal effect on normal mammary epithelial 184A1 cells, which express very low levels of EGFR, suggesting an important contribution of EGFR in delphinidin action. Moreover, delphinidin treatment of AU-565 cells resulted in induction of caspase 3-dependent apoptosis.

Delphinidin has also been shown to induce apoptosis and autophagy in MDA-MB-453 (concentrations of 20, 40 and 80 µM) and BT474 (concentrations of 60, 100 and 140 µM) cell lines [132]. In this study, the autophagy inhibitors, 3-methyladenine (3-MA) or bafilomycin A1 (BA1), enhanced the delphinidin-induced apoptosis in both breast cancer cell lines, suggesting that autophagy might exert a protective effect in this experimental model. In addition, these authors showed that delphinidin induced autophagy via the mTOR and AMPK signaling pathways.

The effect of cyanidin-3-glucoside, the main anthocyanin studied in breast cancer cells, was evaluated on breast cancer-induced angiogenesis [133]. This anthocyanin attenuated breast cancer-induced angiogenesis via inhibiting the expression and secretion of VEGF, the most important angiogenic cytokine, in a dose-dependent manner (concentrations up to 20 µM). The mechanism proposed by these authors involves the downregulation of STAT3, at both mRNA and protein level, via inducing miR-124, resulting in VEGF inhibition. Thus, the inhibitory effect of cyanidin-3-glucoside on the endogenous STAT3 may occur in a non-canonical way, via miRNAs, which could downregulate target gene expression with mRNA degradation.

Recently, Liang et al. [134] reported that cyanidin-3-glucoside (20 µM) decreased the migratory and invasive nature of triple-negative breast cancer cell lines through reversion of the EMT, which is highly associated with cancer metastasis. Cyanidin-3-glucoside increased epithelial markers (E-cadherin and zonula occludens-1), decreased mesenchymal markers (vimentin and N-cadherin) and EMT-associated transcription factors (Snail1, Snail2). Mechanistically, this phytochemical also attenuated the pivotal factor for EMT, NF-κB, and induced the inhibitor Sirt1 in triple-negative breast cancer cell lines.

There is currently available evidence that endogenous estrogens play a critical role in the development of breast cancer [135]. Despite the fact that triple-negative breast cancer is characterized by a lack of ERα expression [136], data suggest that estrogen still plays a critical role in the etiology of this type of cancer since a 36-kDa variant of ERα, known as ER alpha 36 (ERα36), is highly expressed in triple-negative breast cancer [137] and is involved in rapid estrogen signaling [138]. Studies also emphasize the causal link between ERα36 and EGFR, since this receptor is one of the most critical downstream targets of activated ERα36 signaling [138].

Wang et al. [139] found that cyanidin-3-glucoside (150 µM) preferentially promotes cell death, by the extrinsic apoptosis pathway of triple-negative breast cancer cells (MDA-MB-231) that co-express ERα36 and EGFR. Cyanidin-3-glucoside directly binds to the ERα36 receptor, which in turn inhibits its downstream signaling, the EGFR/AKT pathway leading to EGFR degradation through the proteasome system. A xenograft mouse model also confirmed these properties of cyanidin-3-glucoside.

Fernandes et al. [140] evaluated the effect of cyanidin-3-glucoside, delphinidin-3-glucoside, and vinylpyranoanthocyanin-catechins (portisins) on MCF-7 cells. Overall, the studied compounds inhibited, in a dose-dependent manner (12.5–100 µM), the growth of MCF-7 cells, however, delphinidin-3-glucoside and its respective portisin presented the highest cytotoxic effect. This same study also highlighted a structural requirement for a more potent cytotoxicity effect on MCF-7 cells, characterized by an ortho- trihydroxylated substituent attached to the phenolic ring. Nevertheless,
this study was unable to elucidate whether anthocyanins antiproliferative effect could be dependent or independent of ERs or other molecular pathways involved.

Although the monoclonal antibody trastuzumab improves survival of patients with HER2-positive breast cancers [141], the majority of patients who initially respond to this therapy demonstrate disease progression within 12–24 months [142]. Thereby, identifying alternative strategies to overcome trastuzumab resistance targeting HER2 may improve treatment response in breast cancer. Li et al. [143] investigated the antitumor properties of anthocyanins, peonidin-3-glucoside, and cyanidin-3-glucoside, on parental HER2-positive cells and their trastuzumab-resistant cell lines. Treatment with cyanidin-3-glucoside and peonidin-3-glucoside significantly inhibited cell growth in the parental and trastuzumab-resistant cells in a dose-dependent manner. The authors also observed that the mechanisms of action of cyanidin-3-glucoside (5 µg/mL) and peonidin-3-glucoside (5 µg/mL) involve the inhibition of HER2 phosphorylation, the induction of apoptosis in both sensitive and trastuzumab-resistant cell lines, and in a higher anthocyanins concentration (1 mg/mL), an inhibition of trastuzumab-resistant cells migration and invasion was also observed. Besides that, treatment with both anthocyanins (6 mg/Kg/twice weekly, intraperitoneal) reduced trastuzumab-resistant cell-mediated tumor growth in vivo.

As described above, cyanidin-3-glucoside can act alone against breast cancer. However, it has also been shown to be effective in combination with trastuzumab in three representative HER2-positive breast cancer cell lines [144]. These researchers demonstrated that HER2 inactivation seems to represent a central role in the synergistic effect between cyanidin-3-glucoside and trastuzumab in all HER2-positive breast cancer cells tested. Moreover, cyanidin-3-glucoside (5 µg/mL) alone and in combination with trastuzumab (5 µg/mL) induce cell apoptosis in HER2-positive cell lines. These authors also evaluated, in an in vivo xenograft model in mice, the effect of 6 mg/mL cyanidin-3-glucoside in association with 6 mg/mL trastuzumab intraperitoneally twice a week for 25 days. These results demonstrated that anthocyanins were able to significantly enhance trastuzumab-induced tumor growth inhibition.

4. Non-Flavonoid Phenolic Compounds

**Resveratrol**

Natural stilbenes are an important group of non-flavonoid polyphenols characterized by the presence of a 1,2-diphenylethylene nucleus in their structure [145]. Among them, resveratrol (3,4’,5-trihydroxy-trans-stilbene) is a phenolic compound derived from grapes, berries, peanuts, and other plant sources. The molecule consists of two aromatic rings that are connected through a methylenic bridge and exists as cis- and trans-resveratrol isomers (Figure 5), and their glucosides, cis- and trans-piceid [146]. Resveratrol was originally identified as a phytoalexin by Langcake and Pryce [147] and is produced by a wide range of plant species under stressful environmental conditions, such as pathogen infection and ultraviolet radiation. Grapes and their derivative products, particularly red wine, are the most important natural sources of resveratrol. The resveratrol composition of wines depends on the grape varieties used, as well as the growing conditions and the wine-making methods, which may vary. In fresh grape skin, the concentration of this compound is in the range of 50–100 µg per gram, and red wine contains about 1.9 ± 1.7 mg/L of trans-resveratrol [148–152].

In humans, resveratrol is extensively metabolized and rapidly eliminated. When consumed orally, the molecule is absorbed via passive diffusion or by membrane transporters in the intestine, and then conjugated into glucuronides and sulfates. Although oral absorption is around 75%, only a small fraction of resveratrol ingested from dietary sources reaches the bloodstream and body tissues. It was previously described that metabolism in the liver and intestine results in oral bioavailability of about 1–2% of trans-resveratrol [153–155]. Rapid conjugation and low bioavailability are some of the major limitations and challenges of the in vivo use of this compound. Different methodological approaches, such as encapsulation in liposomes, emulsions, micelles, insertion into polymeric nanoparticles, solid dispersions, and nanocrystals, have been developed to improve the low aqueous solubility
and the poor bioavailability of resveratrol [156]. Furthermore, the use of naturally occurring or synthetic resveratrol derivatives, with a better pharmacokinetic profile, low toxicity, less side effects, and improved biological activities, are promising strategies for clinical applications of stilbene compounds [157].

Resveratrol exhibits multiple bioactivities, including anti-oxidative, anti-inflammatory, cardioprotective, neuroprotective, anti-aging and anticancer properties. Accumulated experimental and clinical evidence clearly shows the chemopreventive and chemotherapeutic potential of resveratrol, as reviewed in our recent publication [158]. Scientific interest in this molecule has grown considerably during the last 23 years, since Jang and colleagues first demonstrated the ability of resveratrol to inhibit in vivo carcinogenesis in a mouse skin cancer model [159,160]. Resveratrol is reported to act as a multi-target suppressor of all three carcinogenesis stages (initiation, promotion, and progression), by regulating signal transduction pathways that control cell division and growth, apoptosis, inflammation, angiogenesis, and metastasis. Furthermore, resveratrol increases the efficacy of traditional chemotherapy and radiotherapy by reducing drug resistance and sensitizing tumor cells to a chemotherapeutic agent [160–163].

A plethora of studies, including in vitro and in vivo investigations, have suggested that resveratrol triggers chemopreventive and therapeutic responses against several tumor types, such as skin, breast, prostate, lung, colon, and liver cancer [163,164]. As indicated by a recent search on PubMed (accessed in April 2020), most of these studies (570 of 3524 hits) have been reported in breast cancer models. In 2005, it was shown for the first time that resveratrol from grape consumption is inversely related to breast cancer risk, as reported in a case-control study conducted between 1993 and 2003 in the Swiss Canton of Vaud on 369 cases and 602 controls [165]. Among its wide range of biological properties, resveratrol has attracted considerable attention in breast carcinogenesis because of its role as a phytoestrogen. This compound can compete with natural estrogens for binding to ERs, thus modulating its biological responses [146,155,166,167].

Hormone-dependent tumors may be prevented by regular exposition to selective estrogen receptor modulators (SERMs). These compounds exhibit different levels of estrogen agonism or antagonism, depending on the cell type and gene expression targeted by ERs [168]. Gehm and colleagues were the first to investigate whether resveratrol would have estrogenic activity due to its structural similarity to the synthetic estrogen diethylstilbestrol (DES; 4,4′-dihydroxy-trans-α, β-diethylstilbene). Based on its ability to compete with E2 for binding to and modulating the activity of ERα, resveratrol was characterized as a phytoestrogen [169]. It binds to ER at a low micromolar range (3–10 μM) and with lower affinity than estradiol. Despite this, resveratrol may act as a superagonist in activating hormone receptor-mediated gene transcription in MCF-7 cells [169,170]. In contrast, the antiestrogenic activity of resveratrol in breast cancer was also reported, being related to pathways that inhibit estrogen-induced cellular outcomes, such as proliferation, tumoral transformation, and progression [146]. Lu and Serrero reported ER antagonism of resveratrol (5 μM) in the presence of E2 and partial agonism in its absence [171]. It was also demonstrated that resveratrol exerted a mixed agonist/antagonist action of resveratrol and (b) cis-resveratrol.

**Figure 5.** Structures of stilbenes. (a) Trans-resveratrol and (b) cis-resveratrol.
in cells transiently transfected with ER, and mediated higher transcriptional activity when bound to ERβ than to ERα. Moreover, resveratrol showed antagonist activity with ERα, but not with ERβ [172]. Based on these reports, resveratrol may be categorized as a natural SERM, since it behaves as both agonist and antagonist of ERs. These opposite responses vary according to cell type, resveratrol concentration, hormone competition and ERs expression [155,173]. Resveratrol also modulates the expression of the progesterone receptor (PR). It was previously reported that resveratrol produces greater transcriptional activation of PR than estradiol. In MCF-7 cells, resveratrol was as effective as a maximal dose of estradiol in activating PR gene expression [169].

In tumors, expression of aromatase is upregulated compared to that of surrounding noncancerous tissue. The suppression of in situ estrogen formation by using aromatase inhibitors is a promising route for chemoprevention against breast cancer. In SK-BR-3 cells, resveratrol significantly reduced aromatase mRNA and protein expression in a dose-dependent manner [174]. Resveratrol also inhibits the expression and enzyme activity of aromatase, thus reducing localized estrogen production in breast cancer cells [175]. When tested in a co-culture system of T47D breast cancer cells with human breast adipose fibroblasts (BAFs), resveratrol (20 µM) promoted an aromatase inhibitory effect as potent as 20 nM of letrozole, which is a clinically used anti-aromatase drug in breast cancer treatment [176].

As reviewed by different authors, several experimental approaches have been used to describe the molecular mechanisms of resveratrol in breast carcinogenesis [155,158,162,177]. In addition to the phytoestrogenic action, resveratrol modulates xenobiotic metabolism by altering ABCG2 and CYP1A1 activities [178]; decreases the production of prostaglandins by inhibiting COX-2 expression and activity at multiple levels [177]; suppresses the growth of different breast cancer cell lines and induces a number of biological pathways, thus leading to cell growth arrest and apoptosis [155,165,177,179,180]; modulates the p53 tumor suppressor protein by inducing post-translational modifications [158,180]; prevents mutant p53 aggregation in breast cancer cells and in breast tumor xenografts [181]; regulates extracellular growth factors and receptor tyrosine kinases [162]; induces epigenetic mechanisms by modulation of histone acetylation/methylation [182]; inhibits angiogenesis, EMT, and metastasis [155]; acts as an MDR reversion molecule [183] and sensitizes breast cancer cells toward chemotherapy [161]. In animal studies, resveratrol inhibits chemically-induced breast carcinogenesis; it reduces tumor growth, decreases angiogenesis and increases the apoptotic index in xenograft breast cancer models; delays the tumor development, reduces the mean number and size of tumors and diminished the number of lung metastases in spontaneous breast tumor models [155]. In recent years, accumulating evidence also suggests that resveratrol may be effective in breast cancer management when given in combination with other naturally occurring and chemotherapeutic agents, thus suggesting that resveratrol can enhance the efficacy of other compounds [184].

Although the antitumor activity of resveratrol in in vitro and animal breast cancer models is well established, the clinical evidence regarding its therapeutic effect against breast cancer is still limited. Considering that preclinical and clinical studies suggested that resveratrol may modulate several hormone-related factors involved in breast cancer risk, a pilot phase I clinical study was conducted in a group of forty postmenopausal women with high body mass index, to determine the clinical effect of resveratrol on systemic sex steroid hormones. The resveratrol intervention (1 g daily, for 12 weeks) did not result in significant changes in serum concentrations of estradiol, estrone, or testosterone, but had favorable effects on estrogen metabolism and steroid hormone-binding globulin (SHBG) [185]. Further clinical trials are required to ascertain and validate the efficacy of resveratrol on breast cancer.

5. Grape and Wine Metabolites and Breast Cancer (In Vitro and In Vivo Studies)

The health-promoting effect of wine can be focused on consumption, bioavailability, metabolism and microbiota influence on bioactive compounds. There is now strong evidence that the molecules responsible for those effects are probably not the ingested ones but rather their metabolites that occur after the action of microbiota and absorption process. The identification and quantification of these
metabolites has not been an easy task, but improvement of analytical methods and sensitivity has allowed some advances in metabolomics area [186].

The WinMet database contains 2030 putative compounds present in oenological matrices covering 10 different families, such as phenols, organic acids, biogenic amines, sugars, polyols, fatty acids, higher alcohols, aldehydes, lignans, and ketones [187]. These molecules can be divided into primary metabolites (e.g., sugars, amino acids, and short chain organic acids) and secondary metabolites (flavonoids and phenol compounds) and are well documented in the literature about wines [188].

Wine is a complex mixture of many different molecules and several factors interfere in its composition, such as grape type, fermentation process, aging, among others. For example, catechin and epicatechin decrease during aging in all wines, while gallic acid increases in almost all red wines [189]. Thus, the purpose of this section will be to discuss in vitro and in vivo studies related to the metabolites of the flavonoid and non-flavonoid compounds present in red wine described previously in this review, and the relationship between these molecules and breast cancer.

The majority of phenolic compounds from grapes and wine are metabolized in the gastrointestinal tract, where they are broken down by gut microbiota and typically involve deglycosylation, followed by breakdown of ring structures to produce phenolic acids and aldehydes. These metabolites can be detected in bloodstream, urine, and fecal samples by using sophisticated instrumentation methods for quantitation and identification at low concentrations [190].

An intervention study with red wine offered to eight healthy adults for 20 days revealed significant changes in eight metabolites: 3,5-dihydroxybenzoic acid, 3-O-methylgallic acid, p-coumaric acid, phenylpropionic acid, protocatechuic acid, vanillic acid, syringic acid and 4-hydroxy-5-(phenyl)valeric acid without any influence of ethanol on the microbial action [191]. The same research group characterized the metabolome of human feces after moderate consumption of red wine by healthy subjects during four weeks and showed 37 metabolites related to wine intake, from which 20 could be tentatively or completely identified, including the following: wine compounds, microbial-derived metabolites of wine polyphenols and endogenous metabolites and/or others derived from different nutrient pathways. After wine consumption, fecal metabolome is usually enriched in flavan-3-ols metabolites [192].

To determine which compounds in grapes and wine are the most bioactive, their effects in disease models must be known, including absorption and metabolism. Rats that consume a red wine extract have elevated levels of the microbial phenolic acid metabolites 3-hydroxyphenylpropionic, 3-hydroxybenzoic, 3-hydroxyhippuric, hippuric, p-coumaric, vanillic, 4-hydroxybenzoic, and 3-hydroxyphenylacetic acids in urine. These urine metabolites account for roughly 10% of the administered red wine polyphenols [193]. Most grape and wine flavonoids and others are rapidly metabolized in the human body, making it difficult to determine whether these compounds are effective against disease.

Based on these metabolites, the combination of hippuric acid (HA) nanocomposite (intercalation of hippuric acid into a zinc-layered hydroxide) with doxorubicin and oxaliplatin induced cytotoxicity in MDA-MB-231 and MCF-7 cell lines [194]. 4-Hydroxybenzoic acid (4-HBA) and a histone deacetylase 6 (HDAC6) inhibitor could successfully reverse adriamycin (ADM) resistance in human breast cancer cells. 4-HBA significantly promoted the anticancer effect of ADM on apoptosis induction, as evidenced by the increased expressions of caspase-3 and PARP cleavage, which were associated with the promotion of p53 and homeodomain interacting protein kinase-2 (HIPK2) expressions in ADM-resistant breast cancer cells. Therefore, 4-HBA could be applied as an effective HDAC6 inhibitor to reverse human breast cancer resistance. Herein, the 4-HBA and ADM combination might represent a useful therapeutic strategy to prevent human breast cancer [195].

Apoptotic effects of protocatechuic acid (PCA), another metabolite of wine, were examined on MCF-7 cells. Results showed that PCA concentration-dependently decreased cell viability, increased lactate dehydrogenase leakage, enhanced DNA fragmentation, reduced mitochondrial membrane potential and lowered Na⁺-K⁺-ATPase activity. PCA also concentration-dependently
elevated caspases-3 and -8 activities and significantly inhibited cell adhesion. These findings suggest that PCA is a potent anticancer agent to cause apoptosis or retard invasion and metastasis in breast cancer and other cells [196].

The metabolites gallic acid, 4-O-methylgallic acid and 3-O-methylgallic acid are detected in the plasma of humans who consume 300 mL of red wine [197]. In fact, the metabolites gallic acid and 4-O-methylgallic acid are well correlated with wine consumption and may be used as urinary biomarkers for wine intake in health-related studies [198]. Phenolic acid metabolites are mainly formed from gut microbiota metabolism and could be responsible for much of the disease reduction associated with consuming wine and grape phenolics.

Gallic acid (GA) possesses potential for antitumoral activity on different types of malignancies. GA treatment significantly decreased the cell viability of MDA-MB-231 and HS578T cells in a dose-dependent manner. In addition, GA exerted relatively lower cytotoxicity on non-cancer breast fibroblast MCF-10F. The changes in cell cycle distribution in response to GA treatment led to an increase of G0/G1 and sub-G1 phase ratio in MDA-MB-231 cells. GA also downregulated cyclin D1/CDK4 and cyclin E/CDK2, upregulated p21Cip1 and p27Kip1 and induced activation of caspase-9 and caspase-3. In addition, it modulated p38 mitogen-activated protein kinase that was involved in the GA-mediated cell-cycle arrest and apoptosis. GA inhibited the cell viability of TNBC cells, which may be related to the G1 phase arrest and cellular apoptosis via p38 mitogen-activated protein kinase/p21/p27 axis. Thus, GA could be beneficial for TNBC treatment [199]. GA also promoted inhibition of proliferation and induction of apoptosis in MCF-7 cells. The results revealed that GA induced apoptosis by triggering the extrinsic or Fas/FasL pathway as well as the intrinsic or mitochondrial pathway. Furthermore, the apoptotic signaling induced by GA was amplified by a cross-link between the two pathways. Taken together, these findings may be useful for understanding the mechanism of action of GA on breast cancer cells and provide new insights into the possible application of such a compound and its derivatives in breast cancer therapy [200].

5.1. Resveratrol Metabolites

Resveratrol is a minor component of red wines and, following its ingestion, it is converted to glucuronide and sulfate metabolites, which are present in the circulatory system in nanomolar concentrations [201]. Nevertheless, the by far most commonly studied form of resveratrol is the aglycone, often at concentrations largely exceeding those attainable in vivo. By contrast, very little is known about the biological activity of the resveratrol metabolites formed upon intestinal absorption, which represent the major circulating forms of resveratrol; in particular, the glucuronic acid and the sulfate conjugates of trans-resveratrol, which are produced at the enterocyte and hepatocyte level [202]. Besides dihydroresveratrol, Bode et al. [203] found, in vivo and in vitro, bacterial trans-resveratrol metabolites: 3′,4-dihydroxy-trans-stilbene and 3′,4′-dihydroxybibenzyl (lunularin). In estrogen-sensitive cancer cells, like MCF-7, 3′,4-dihydroxy-trans-stilbene showed agonist properties [204].

Resveratrol-3-O-sulfate (R3S), but no other resveratrol derivative, exerted a pronounced antiestrogenic activity on both receptors (α and β), with a marked preference for ER. R3S, the main resveratrol metabolite accumulating in human plasma after ingestion of dietary amounts of resveratrol, is an effective ER-preferential anti-estrogen in both yeast and mammalian cells [205]. A significant increase in MCF-7 cancer cells growth rates was shown in the presence of picomolar concentrations of dihydroresveratrol (DH-RSV) because this polyphenol has a profound proliferative effect on hormone-sensitive tumor cell lines such as MCF-7.

The proliferative effect of DH-RSV was not observed in cell lines that do not express hormone receptors (MDA-MB-231, BT-474 and K-562) [206]. Human MCF-7 (wild-type p53), MDA-MB-231 (mutant p53) and nontumorigenic MCF-10A cells are treated with resveratrol and physiological-derived metabolites (RSV-3-O-glucuronide, RSV-3-O-sulfate, RSV-4′-O-sulfate, DH-RSV and DH-RSV-3-O-glucuronide). Cellular senescence is measured by SA-β-gal activity and senescence-associated markers (p53, p21Cip1/Waf1, p16INK4a and phosphorylation status
of retinoblastoma (pRb/tRb). While no effect is observed in MDA-MB-231 and normal cells, resveratrol metabolites induce cellular senescence in MCF-7 cells by reducing their clonogenic capacity and arresting cell cycle at the G2M/S phase, but do not induce apoptosis. Senescence is induced through the p53/p21Cip1/Waf1 and p16INK4a/Rb pathways, depending on the resveratrol metabolite, and requires ABC transporters, but not ERs. Recent evidence demonstrates that resveratrol metabolites, but not free resveratrol, reach malignant tumors (MT) in breast cancer (BC) patients. Since these metabolites, as detected in MT, do not exert short-term antiproliferative or estrogenic/antiestrogenic activities, long-term tumor senescent chemoprevention has been hypothesized. These data suggest that resveratrol metabolites, as found in MT from BC patients, are not deconjugated to release free resveratrol, but enter the cells and may exert long-term tumor-senescent chemoprevention [207].

5.2. Catechins Metabolites

Catechin appears to be metabolized only if absorbed from the small intestinal lumen. Both 3′-O-methylcatechin-glucuronide and catechin-glucuronide are produced in intestinal cells and methylation and sulfation of catechin metabolites occur in the liver [208]. Catechin glucuronide and 3′-O-methylcatechin glucuronide are mainly found in plasma of rats after ingestion of catechins [208,209]. Large amounts of the 3′-O-methyl metabolite are also found to be glucuronidated and sulfated on the same compound, presumably produced in the liver, and are only detected in the bile [208]. In humans, between 3.0 and 10.3% of ingested catechins from red wine are accounted for in urine, mostly as catechin and its 39-O-methyl-glucuronide and sulfate metabolites [210].

Aside from metabolism that occurs in intestinal cells and liver, catechins can also be metabolized by gut microbiota to produce phenolic acid metabolites. In rats, these metabolites can be found in urine, being 3-hydroxyphenylpropionic acid, 3-hydroxybenzoic acid and 3-hydroxyhippuric acid present in the highest concentrations [193]. When catechin is incubated with human gut microbiota, it is metabolized to 4-hydroxybenzoic acid, 2,4,6-trihydroxybenzaldehyde, phloroglucinol and 4-methoxysalicylic acid [211], again emphasizing the effects of individual microbiota profiles on gut metabolism. We have not found much research showing the association of catechin metabolites with breast cancer, only with the use of phloroglucinol, as can be seen above.

Metastasis is a challenging clinical problem and the primary cause of death in breast cancer patients. Treatment with phloroglucinol (PG) effectively inhibited mesenchymal phenotypes of basal type breast cancer cells through downregulation of SLUG without causing a cytotoxic effect. Importantly, PG decreased SLUG through inhibition of PI3K/AKT and RAS/RAF-1/ERK signaling. Treatment with PG sensitized breast cancer cells to anticancer drugs such as cisplatin, etoposide, and taxol, as well as to ionizing radiation. Taken together, these data indicate PG to be a good candidate to target breast cancer stem-like cells (BCSCs) and to prevent disease relapse [212,213].

5.3. Anthocyanins Metabolites

In humans, nanomolar plasma concentrations of anthocyanins are found after they are consumed. Anthocyanins such as cyanidin-3-glucoside and pelargonidin-3-glucoside could be absorbed in their intact form into the gastrointestinal wall, undergo extensive first-pass metabolism, and enter the systemic circulation as metabolites. Phenolic acid metabolites were found in the bloodstream in much higher concentrations than their parent compounds. These metabolites could be responsible for the health benefits associated with anthocyanins [214].

After rats ate cyanidin-3-glucoside, the aglycone was only found in the small intestine, cyanidin-3-glucoside was found in the plasma, and methylated cyanidin-3-glucoside was found in the liver and kidney [215]. Cyanidin-3-glucoside attenuates the angiogenesis of breast cancer via inhibiting STAT3/VEGF pathway [133].

In humans and Caco-2 cells, cyanidin-3-O-glucoside’s major metabolites are protocatechuic acid (PCA) and phloroglucinaldehyde which are also subjected to entero-hepatic recycling, although caffeic acid andpeonidin-3-glucoside seem to be strictly produced in the large bowel and renal tissues [216].
Previous studies evaluated the bioavailability of anthocyanins using red wine and dealcoholized red wine [217,218]. One of the first studies is the work of Bub and co-workers who only detected the main native anthocyanin in plasma and urine with no effect of ethanol on the amount quantified [217]. Ethanol enhances cyanidin-3-O-glucoside’s metabolism potentiating its conversion into methylated and glucuronidated derivatives, showing an increase in the two main anthocyanin conjugates, methyl-cyanidin-glucuronide and 3'-methyl-cyanidin-3-O-glucoside, of 59% and 57%, respectively. But in this case, the food matrix used was blackberry puree with or without ethanol, and not wine or grapes [219].

The accumulation of multiple phenolic metabolites might ultimately be responsible for reported anthocyanin bioactivity, with the gut microbiota apparently playing an important role in the biotransformation process. Nevertheless, phase II conjugates of cyanidin-3-O-glucoside and cyanidin (cyanidin-glucuronide, methyl cyanidin and methyl-cyanidin-glucuronide) were also detected in plasma and urine [186]. The most important metabolites corresponded to products of anthocyanin degradation (i.e., benzoic, phenylacetic and phenylpropenoic acids, phenolic aldehydes and hippuric acid) and their phase II conjugates, which were found at 60- and 45-fold higher concentrations than their parent compounds in urine and plasma, respectively [220].

Delphinidin-3-glucoside, cyanidin-3-glucoside and petunidin-3-glucoside methylated metabolites were obtained by enzymatic hemi-synthesis and decreased or did not alter the antiproliferative effect of the original anthocyanin in MCF-7 cells [221]. The methylation reaction alters the number of hydroxyl and methoxyl groups in ring B, so these metabolites are likely to have different antioxidant activities in comparison with the original anthocyanins. Generally, the health effects of anthocyanins are associated with an increase in the endogenous antioxidant defenses. In a paper by Fernandes et al. [221] the synthetized methylated metabolites still displayed some antiproliferative activities for the three cell lines although not as intense as parental anthocyanin. The biological studies conducted with the metabolites in comparison with the native compounds allow understanding of the real contribution of methylation towards the antioxidant and antiproliferative effects of anthocyanins. However, this subject is new and needs more publications for a good discussion, especially from methylated anthocyanin-derived metabolites.

5.4. Quercetin Metabolites

Quercetin or its metabolites may have cytotoxic activities [222]. Studies on the metabolism of quercetin suggest degradation by intestinal microbiota and relatively low absorption [223], limiting its use as a biomarker. Metabolism of quercetin includes 3,4-dihydroxyphenylacetic acid (DHPAA) as homoprotocatechuic acid, m-hydroxyphenylacetic acid (mHPAA), and 3-methoxy-4-hydroxyphenylacetic acid as homovanillic acid (HVA) [224]. These three metabolites are excreted in the urine of rats, rabbits, and humans [224,225].

Recently, Yamazaki et al. [226,227] investigated the effects of quercetin and its main circulating metabolite quercetin-3-O-glucuronide on MCF-10A and MDA-MB-231 cells and suggested that these flavonoids may suppress invasion of these cells by controlling β2-adrenergic signaling, and may be a dietary chemopreventive factor for stress-related breast cancer.

5.5. Metabolites and Breast Cancer Patients

In relation to breast cancer patients, previous reports have shown that glycolysis, lipogenesis and the production of volatile organic metabolites were increased in the serum of these patients compared to healthy women [228]. The serum levels of choline, tyrosine, valine, lactate, isoleucine are up-regulated, and glutamate levels are downregulated in patients with early-stage breast cancer [229]. These studies reveal that metabolic alterations are important indications for breast cancer. There is evidence that metabolic changes are correlated with metastasis and metabolism of tumors [230–232]. Metabolism changes are often associated with resistance to chemotherapy and therapeutic sensitivity in clinical chemotherapy. Breast cancer cells not only show significant differences in metabolism compared
with healthy breast cells, but also show differences in drug resistance [233,234]. Cancer and metabolism are deeply interconnected, studies indicate that cancer evolution is associated with abnormal glucose metabolism that is related to high proliferation, metastasis and clinical characteristics and is allied to the action of a particular drug. In this context, chemoresistance enables cancer cells to survive drug action and proliferate uncontrollably, which may lead to strong metastatic potential and cancer progression [230–234].

A recent clinical trial has reported resveratrol accumulation, mainly as sulfates and glucuronides, in normal and malignant human breast tissues. Although phase-II conjugation might hamper a direct anticancer activity, long-term tumor-senescent chemoprevention cannot be discarded [235]. Metabolites of wine bioactive compounds have been positively related to in vitro and in vivo breast anticancer properties and this evidence was associated with the ingestion of several flavonoids present in large amounts in red wine. However, the concentration required to trigger a biological event is dependent not only on the amount ingested, but also on critical variables that include bioaccessibility, bioavailability, stability under in vivo conditions, and so on. Many studies are still required to clarify the role of many of these metabolites with regard to the health-promoting properties of wine.

Table 1 summarizes the data collected from the literature about the metabolite dosage used or found in the different in vitro and in vivo models mentioned in this review.
Table 1. Summary of metabolites found or used in different in vitro and in vivo models.

| Dietary Factor/Isolated Compound | Model (Human/Animal/Cancer Cell Lines) | Sample Type | Discriminating Metabolites | Average of Metabolites (Found or Used) | Primary Reference |
|---------------------------------|----------------------------------------|-------------|-----------------------------|----------------------------------------|-------------------|
| Red wine                        | Human (healthy subjects)               | Plasma      | catechin, gallic acid, 4-O-methylgallic acid, 3-O-methylgallic acid, caffic acid | 0.13–1.5 µmol/L [197] |                   |
|                                 |                                        |             | trans-resveratrol, trans-resveratrol-4′-O-glucuronide, trans-resveratrol-3′-O-glucuronide | 0–0.03 µM, 0–3.9 µM, 0–2.7 µM | [201]             |
| Red wine resveratrol in capsules| Human (healthy subjects)               | Plasma      | resveratrol-O-glucuronide, resveratrol-O-sulfate | 0.56–2.90 µM, 0.75–4.78 µM |                   |
| Red wine and red grape juice    | Human (male healthy subjects)          | Plasma, Urine | cyanidin 3-glucoside, delphinidin 3-glucoside, malvidin 3-glucoside, peonidin 3-glucoside, petunidin 3-glucoside | 0.42–48.8 ng/mL (maximum), 0.66–86.7 µg/h | [218]             |
| Red wine, dealcoholized red wine| Human (male healthy subjects)          | Plasma, Urine | malvidin-3-glucoside | 1.38 nM (maximum), 13.5–27.0 µg | [217]             |
| and grape juice                 |                                        |             | 3,4-dihydroxyphenylacetic acid, m-hydroxyphenylacetic acid, homovanillic acid | 0.7 µg/mL, 4.8 µg/mL, 2.8 µg/mL | [225]             |
| Habitual diets                  | Human (healthy subjects)               | Urine       | catechin (unmethylated conjugates), catechin (methylated conjugates) | 0–79.8 µmol | [210]             |
| Red wine and dealcoholized red wine| Human (healthy subjects)               | Urine       | gallic acid, 4-O-methylgallic acid, 3,5-dihydroxybenzoic acid, protocatechuic acid, 3-O-methylgallic acid, vanillic acid, syringic acid, p-coumaric acid, phenylpropionic acid, 4-hydroxy-5(phenyl)valeric acid, 2,2′-pentanedione, diethylmalonate, 2-phenethyl butyrate, 2-phenylethyl hexanoate, 5-(3′,4′,4′-dihydroxyphenyl)gamma-valerolactone, 3-(3′-hydroxyphenyl)propionic acid, 4-hydroxy-5-(phenyl)valeric acid, benzonic acid, 4-hydroxy-5-(phenyl)valeric acid | 0.2–50 µg/g | [191]             |
| Wine                            | Human (healthy subjects)               | Urine       | 4-hydroxybenzoic acid | 1.6–6.1 µmol/d | [198]             |
| Red wine and dealcoholized red wine| Human (healthy adults)                 | Human feces | 3,4-dihydroxyphenyl)gamma-valerolactone, 4-hydroxy-5(phenyl)valeric acid, benzonic acid, 4-hydroxy-5-(phenyl)valeric acid | 0.2–50 µg/g | [191]             |
| Catechin                        | Human (healthy subjects)               | Feces       | 2,4,6-trihydroxybenzoic acid, phloroglucinol | Not determined | [211]             |
| trans-resveratrol               | Human (healthy subjects)               | Feces       | 3,4′-dihydroxy-trans-stilbene | 0–11.1 µmol/L | [203]             |
Table 1. Cont.

| Dietary Factor/Isolated Compound | Model (Human/Animal/Cancer Cell Lines) | Sample Type | Discriminating Metabolites | Average of Metabolites (Found or Used) | Primary Reference |
|---------------------------------|----------------------------------------|-------------|-----------------------------|---------------------------------------|-------------------|
| Fried onions, quercetin rutinoside, quercetin aglycone | Human (healthy ileostomy subjects) | Ileostomy effluent urine | Quercetin | 37–72 mg 73–279 µg | [223] |
| Isotopically labeled cyanidin-3-glucoside (6,8,10,3′,5′-labeled C3G) | Human (male healthy subjects) | Serum | PCA-3-sulfate, PCA-4-sulfate, vanillic acid, isoavicular acid, vanillic acid-glucuronide, isoavicular acid-sulfate, methyl 3,4-dihydroxybenzoate, 2-hydroxy-4-methoxybenzoic acid, methyl vanillate, 3,4-dihydroxyphenylacetic acid, caffeic acid, ferulic acid, hippuric acid | 6.11 µmol/L (maximum) 15.69 µmol/L (maximum) | [220] |
| Red wine powder | Animal (male Wistar rats) | Urine | Aromatic acids | 4.7–2790 µg/d 0.6–3 µg/d | [193] |
| (+)-Catechin | Animal (male Wistar rats) | Plasma | Catechin | 60–110 µmol/L 0.2–2.8 µmol/L | [208] |
| (+)-Epicatechin | Animal (male Sprague-Dawley rats) | Urine | Epicatechin | 0.3–19.3 µmol/L 0.1–0.8 µmol/L | [209] |
| Cyanidin 3-O-β-D-glucoside | Animal (male Wistar rats) | Kidney | Methylated cyanidin 3-O-β-D-glucoside | 0–2.56 µmol/L 0.3–20 µmol/L 0–1.32 µmol/L | [215] |
| Rutin | Animal (rabbits) | Urine | Methylated cyanidin 3-O-β-D-glucoside | 0–0.64 µmol/L | [224] |
| Phloroglucinol | Animal (athymic Balb/c female nude mice) | Mice | Phloroglucinol | 25 mg/kg of body | [213] |
| Hippuric acid associated with doxorubicin or oxaliplatin | Cancer cell lines (MDA-MB-231, MCF-7, Caco-2) | Cells | Hippuric acid associated with doxorubicin or oxaliplatin | 0.13–20 µg/mL (IC50) | [194] |
| 4-hydroxybenzoic acid | Cancer cell lines (MCF-7, adriamycin-resistant cells MCF-7/ADM), MDA-MB-231, MDA-MB-468, 4T1 Animal (BALB/c mice) | Cells | 4-hydroxybenzoic acid | 0–20 µM 2 mg/kg | [195] |
### Table 1. Cont.

| Dietary Factor/Isolated Compound | Model (Human/Animal/Cancer Cell Lines) | Sample Type | Discriminating Metabolites | Average of Metabolites (Found or Used) | Primary Reference |
|----------------------------------|----------------------------------------|-------------|-----------------------------|---------------------------------------|-------------------|
| Protocatechuic acid              | Cancer cell lines (MCF-7, A549, HepG2, HeLa, LNCap) | Cells       | protocatechuic acid         | 1–8 µmol/L                            | [196]             |
| Gallic acid                      | Cancer cell lines (MDA-MB-231, H578T, MCF-7) | Cells       | gallic acid                 | 5–400 µM                              | [199]             |
| Resveratrol Hydroxystilbenes     | Cancer cell lines (MCF-7, MDA-MB-231, BT-474, K-562) | Cells       | resveratrol, hydroxystilbenes | 1 nM–10 µM                            | [206]             |
| Resveratrol-3-O-sulfate          | Cancer cell line (MCF-7)               | Cells       | resveratrol-3-O-sulfate     | 500 nM–100 µM                         | [205]             |
| Resveratrol-3′-O-glucuronide     | Cancer cell lines (MCF-7, MDA-MB-231)   | Cells       | resveratrol-3′-O-glucuronide| 0.4–10 µmol/L                         | [207]             |
| Phloroglucinol                   | Cancer cell lines (BT549, MDA-MB-231, MCF-7, SK-BR3, BT549) | Cells       | phloroglucinol              | 0–100 µM                              | [212]             |
| Delphinidin-3-glucuronide        | Cancer cell lines (MKN-28, Caco-2, MCF-7) | Cells       | delphinidin-3-glucuronide   | 6.3–100 µM                            | [221]             |
| Cyanidin-3-glucuronide           | Cancer cell lines (MKN-28, Caco-2, MCF-7) | Cells       | cyanidin-3-glucuronide      |                                       |                   |
| Petunidin-3-glucuronide          | Cancer cell lines (MKN-28, Caco-2, MCF-7) | Cells       | petunidin-3-glucuronide     |                                       |                   |
| Quercetin-3-O-glucuronide        | Non-tumorigenic cell line (MCF-10A) and cancer cell line (MCF-MB-231) | Cells       | quercetin-3-O-glucuronide   | 0.01–µM                               | [226]             |
6. Conclusions

As can be seen in this compilation, grapes and wines are rich and complex sources of bioactive molecules with multiple targets and effects. The natural polyphenols from these dietary products belong to different classes of compounds, both flavonoid and non-flavonoid, and have been studied in different models of breast cancer, both in vivo and in vitro. The major anticancer activities promoted by these compounds are summarized in Figure 1 and include modulation of estrogen cell signaling, cancer cell differentiation, cell growth inhibition, apoptosis induction and suppression of the metastatic behavior.

Based on dietary source, bioactive compounds or their metabolites used in different in vitro and in vivo studies for breast cancer, we conclude that there is a great variation of doses utilized or found. When the studies utilize wine or grape as a bioactive compound source, it is possible to observe a great variation on metabolite quality and quantity. On the other hand, when the isolated metabolite or its precursor were used, mainly in cancer cell lines, variations from 1 nM until 100 µM were used, and some authors justify the use of these concentrations to approximate the physiological concentrations. It is also important to point out that the effects produced by the glycosidic forms and the aglycones might lead to different routes of absorption and/or metabolization, leading to important variations in bioavailability and global effects produced.

The bioavailability of these compounds is another important issue that must be circumvented to improve local biological effects. In this way, grape and wine have long been used as sources of lead compounds in the search for breast cancer chemotherapy candidates and should be further explored in clinical studies, along with the biotechnological improvements necessary for their application.

Author Contributions: Writing—original draft preparation—D.C.F.d.C., L.P.R., J.Q., R.A.S., E.F.; writing and editing—D.C.F.d.C., L.P.R., J.L.S., E.F.; All authors have read and agreed to the published version of the manuscript.

Funding: This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)—Finance Code 001, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. The International Agency for Research on Cancer (IARC) Report, World Health Organization (WHO). Latest Global Cancer Data: Cancer Burden Rises to 18.1 Million New Cases and 9.6 Million Cancer Deaths in 2018; IARC: Lyon, France, 2018.
2. Teixeira, A.; Baenas, N.; Dominguez-Perles, R.; Barros, A.; Rosa, E.; Moreno, D.A.; Garcia-Viguera, C. Natural bioactive compounds from winery by-products as health promoters: A review. Int. J. Mol. Sci. 2014, 15, 15638–15678. [CrossRef]
3. Amor, S.; Châlons, P.; Aires, V.; Delmas, D. Polyphenol Extracts from Red Wine and Grapevine: Potential Effects on Cancers. Diseases 2018, 6, 106. [CrossRef] [PubMed]
4. Holliday, D.L.; Speirs, V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011, 13, 1–7. [CrossRef] [PubMed]
5. Agarwal, C.; Sharma, Y.; Zhao, J.; Agarwal, R. A polyphenolic fraction from grape seeds causes irreversible growth inhibition of breast carcinoma MDA-MB468 cells by inhibiting mitogen-activated protein kinases activation and inducing G1 arrest and differentiation. Clin. Cancer Res. 2000, 6, 2921–2930. [PubMed]
6. Leone, A.; Longo, C.; Gerardi, C.; Trosko, J.E. Pro-apoptotic effect of grape seed extract on MCF-7 involves transient increase of gap junction intercellular communication and Cx43 up-regulation: A mechanism of chemoprevention. Int. J. Mol. Sci. 2019, 20, 3244. [CrossRef]
7. Dinicola, S.; Pasqualato, A.; Cucina, A.; Coluccia, P. Grape seed extract suppresses MDA-MB231 breast cancer cell migration and invasion. Eur. J. Nutr. 2014, 53, 421–431. [CrossRef]
8. Lu, J.; Zhang, K.; Chen, S.; Wen, W. Grape seed extract inhibits VEGF expression via reducing HIF-1α protein expression. Carcinogenesis 2009, 30, 636–644. [CrossRef]
9. Eng, E.T.; Williams, D.; Mandava, U.; Kim, N.; Tekmal, R.R.; Chen, S. Anti-Aromatase Chemicals in Red Wine. *Ann. N. Y. Acad. Sci.* 2006, 1079, 236–246. [CrossRef]

10. Kijima, I.; Phung, S.; Hur, G.; Kwok, S.L.; Chen, S. Grape seed extract is an aromatase inhibitor and a suppressor of aromatase expression. *Cancer Res.* 2006, 66, 5960–5967. [CrossRef]

11. Sharma, G.; Tyagi, A.K.; Singh, R.P.; Chan, D.C.F.; Agarwal, R. Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells. *Breast Cancer Res. Treat.* 2004, 85, 1–12. [CrossRef]

12. Yousef, M.I.; Mahdy, M.A.; Abdou, H.M. The potential protective role of grape seed proanthocyanidin extract against the mixture of carboplatin and thalidomide induced hepatotoxicity and cardiotoxicity in male rats. *Prev. Med. Commun. Health* 2020, 2, 1–7. [CrossRef]

13. Makris, D.P.; Kallithraka, S.; Kefalas, P. Flavonols in grapes, grape products and wines: Burden, profile and influential parameters. *J. Food Compos. Anal.* 2006, 19, 396–404. [CrossRef]

14. Simonetti, P.; Pietta, P.; Testolin, G. Polyphenol content and total antioxidant potential of selected Italian wines. *J. Agric. Food Chem.* 1997, 45, 1152–1155. [CrossRef]

15. Gardner, P.T.; McPhail, D.B.; Crozier, A.; Duthie, G.G. Electron spin resonance (ESR) spectroscopic assessment of the contribution of quercetin and other flavonols to the antioxidant capacity of red wines. *J. Sci. Food Agric.* 1999, 79, 1011–1014. [CrossRef]

16. McDonald, M.S.; Hughes, M.; Burns, J.; Lean, M.E.J.; Matthews, D.; Crozier, A. Survey of the Free and Conjugated Myricetin and Quercetin Content of Red Wines of Different Geographical Origins. *J. Agric. Food Chem.* 1998, 46, 368–375. [CrossRef]

17. Dabeek, W.M.; Marra, M.V. Dietary quercetin and kaempferol: Bioavailability and potential cardiovascular-related bioactivity in humans. *Nutrients* 2019, 11, 2288. [CrossRef]

18. Kennedy, J.A. Grape and wine phenolics: Observations and recent findings. *Ciencia e Investigación Agraria* 2008, 35, 107–120. [CrossRef]

19. Fernández de Simón, B.; Hernández, T.; Cadahía, E.; Dueñas, M.; Estrella, I. Phenolic compounds in a Spanish red wine aged in barrels made of Spanish, French and American oak wood. *Eur. Food Res. Technol.* 2003, 216, 150–156. [CrossRef]

20. Castellari, M.; Piermattei, B.; Arfelli, G.; Amati, A. Influence of aging conditions on the quality of red Sangiovese wine. *J. Agric. Food Chem.* 2001, 49, 3672–3676. [CrossRef]

21. Makris, D.P.; Rossiter, J.T. Heat-induced, metal-catalyzed oxidative degradation of quercetin and rutin (quercetin 3-O-rhamnosylglucoside) in aqueous model systems. *J. Agric. Food Chem.* 2000, 48, 3830–3838. [CrossRef]

22. Hashemzaei, M.; Far, A.D.; Yari, A.; Heravi, R.E.; Tabrizian, K.; Taghdisi, S.M.; Sadegh, S.E.; Tsarouhas, K.; Kouretas, D.; Tzanakakis, G.; et al. Anticancer and apoptosis-inducing effects of quercetin in vitro and in vivo. *Oncol. Rep.* 2017, 38, 819–828. [CrossRef] [PubMed]

23. Imran, M.; Salehi, B.; Sharifi-Rad, J.; Gondal, T.A.; Saeed, F.; Imran, A.; Shahbaz, M.; Fokou, P.V.T.; Arshad, M.U.; Khan, H.; et al. Kaempferol: A key emphasis to its anticancer potential. *Molecules* 2019, 24, 2277. [CrossRef] [PubMed]

24. Franke, A.A.; Custer, L.J.; Wilkens, L.R.; Le Marchand, L.; Nomura, A.M.Y.; Goodman, M.T.; Kolonel, L.N. Liquid chromatographic-photodiode array mass spectrometric analysis of dietary phytoestrogens from human urine and blood. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 2002, 777, 45–59. [CrossRef]

25. Wang, L.; Lee, I.M.; Zhang, S.M.; Blumberg, J.B.; Buring, J.E.; Sesso, H.D. Dietary intake of selected flavonols, flavones, and flavonoid-rich foods and risk of cancer in middle-aged and older women. *Am. J. Clin. Nutr.* 2009, 89, 905–912. [CrossRef] [PubMed]

26. Mokbel, K.; Mokbel, K. Chemoprevention of Breast Cancer with Vitamins and Micronutrients: A Concise Review. *In Vivo* 2019, 33, 983–997. [CrossRef]

27. Wang, X.; Yang, Y.; An, Y.; Fang, G. The mechanism of anticancer action and potential clinical use of kaempferol in the treatment of breast cancer. *Biomed. Pharmacother.* 2019, 117, 109086. [CrossRef]

28. Tang, S.M.; Deng, X.T.; Zhou, J.; Li, Q.P.; Ge, X.X.; Miao, L. Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects. *Biomed. Pharmacother.* 2020, 121, 109604. [CrossRef]

29. Barve, A.; Chen, C.; Hebbar, V.; Desiderioa, J.; Constance Lay-Lay Saw, A.-N.K. Metabolism, oral bioavailability and pharmacokinetics of chemopreventive kaempferol in rats. *Biopharm. Drug Dispos.* 2009, 30, 356–365. [CrossRef]
30. Zabela, V.; Sampath, C.; Oufir, M.; Moradi-Afrapoli, F.; Butterweck, V.; Hamburger, M. Pharmacokinetics of dietary kaempferol and its metabolite 4-hydroxyphenylacetic acid in rats. *Fitoterapia* **2016**, *115*, 189–197. [CrossRef]

31. Lamson, D.W.; Brignall, M.S. Antioxidants and cancer III: Quercetin. *Altern. Med. Rev.* **2000**, *5*, 196–208.

32. Cai, X.; Fang, Z.; Dou, J.; Yu, A.; Zhai, G. Bioavailability of Quercetin: Problems and Promises. *Curr. Med. Chem.* **2013**, *20*, 2527–2582. [CrossRef] [PubMed]

33. Liu, L.; Liu, C.; Chen, C.; Yu, X.; Chen, G.; Shi, Y.; Qin, F.; Ou, J.; Qiu, K.; Li, G. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer. *Oncotarget* **2016**, *7*, 32184–32199. [CrossRef] [PubMed]

34. Kubatka, P.; Kapinová, A.; Kello, M.; Kruzlíak, P.; Kajo, K.; Výbohová, D.; Mahmood, S.; Murin, R.; Viera, T.; Mojiš, J.; et al. Fruit peel polyphenols demonstrate substantial anti-tumour effects in the model of breast cancer. *Eur. J. Nutr.* **2015**, *55*, 955–965. [CrossRef]

35. Leigh Ackland, M.; Van De Waarsenburg, S.; Jones, R. Synergistic antiproliferation action of the flavonols quercetin and kaempferol in cultured human cancer cell lines. *In Vivo* **2005**, *19*, 69–76.

36. Yi, X.; Zuo, J.; Tan, C.; Xian, S.; Luo, C.; Chen, S.; Yu, L.; Luo, Y. Kaempferol, a flavonoid compound from gynura medica induced apoptosis and growth inhibition in MCF-7 breast cancer cell. *Afr. J. Tradit. Complement. Altern. Med.* **2016**, *13*, 210–215. [CrossRef]

37. Choi, E.J.; Ahn, W.S. Kaempferol induced the apoptosis via cell cycle arrest in human breast cancer MDA-MB-453 cells. *Nutr. Res. Pract.* **2008**, *2*, 322–325. [CrossRef]

38. Kang, G.Y.; Lee, E.R.; Kim, J.H.; Jung, J.W.; Lim, J.; Kim, S.K.; Cho, S.G.; Kim, K.P. Downregulation of PLK-1 expression in kaempferol-induced apoptosis of MCF-7 cells. *Eur. J. Pharmacol.* **2009**, *611*, 17–21. [CrossRef]

39. Li, S.; Yan, T.; Deng, R.; Jiang, X.; Xiong, H.; Wang, Y.; Yu, Q.; Wang, X.; Chen, C.; Zhu, Y. Low dose of kaempferol suppresses the migration and invasion of triple-negative breast cancer cells by downregulating the activities of RhoA and Rac1. *OncoTargets Ther.* **2017**, *10*, 4809–4819. [CrossRef]

40. Zhu, L.; Xue, L. Kaempferol suppresses proliferation and induces cell cycle arrest, apoptosis, and DNA damage in breast cancer cells. *Onco. Res.* **2019**, *27*, 629–634. [CrossRef] [PubMed]

41. Ranganathan, S.; Halagowder, D.; Sivasithambaram, N.D. Quercetin suppresses twist to induce apoptosis in MCF-7 breast cancer cells. *PLoS ONE* **2015**, *10*, 1–21. [CrossRef] [PubMed]

42. Kabala-Dzik, A.; Rezepcka-Stojko, A.; Kubina, R.; Iriti, M.; Wojtczak, R.D.; Buszman, E.; Stojko, J. Flavonoids, bioactive components of propolis, exhibit cytotoxic activity and induce cell cycle arrest and apoptosis in human breast cancer cells MDA-MB-231 and MCF-7—A comparative study. *Cell. Mol. Biol.* **2018**, *64*, 1–10. [CrossRef] [PubMed]

43. Kim, B.W.; Lee, E.R.; Min, H.; Jeong, H.S.; Ahn, J.Y.; Kim, J.H.; Choi, H.Y.; Choi, H.; Eun, Y.K.; Se, P.P.; et al. Sustained ERK activation is involved in the kaempferol-induced apoptosis of breast cancer cells and is more evident under 3-D culture condition. *Cancer Biol. Ther.* **2008**, *7*, 1080–1089. [CrossRef]

44. Liao, W.; Chen, L.; Ma, X.; Jiao, R.; Li, X.; Wang, Y. Protective effects of kaempferol against reactive oxygen species-induced hemolysis and its antiproliferative activity on human cancer cells. *Eur. J. Med. Chem.* **2016**, *114*, 24–32. [CrossRef]

45. Zhang, H.; Zhang, M.; Yu, L.; Zhao, Y.; He, N.; Yang, X. Antitumor activities of quercetin and quercetin-5′,8-disulfonate in human colon and breast cancer cell lines. *Food Chem. Toxicol.* **2012**, *50*, 1589–1599. [CrossRef]

46. Wu, Q.; Needs, P.W.; Lu, Y.; Kroon, P.A.; Ren, D.; Yang, X. Different antitumor effects of quercetin, quercetin-3′-sulfate and quercetin-3-glucuronide in human breast cancer MCF-7 cells. *Food Funct.* **2018**, *9*, 1736–1746. [CrossRef]

47. Niazvand, F.; Orazizadeh, M.; Khorsandi, L.; Abbaspour, M.; Mansouri, E.; Khodadadi, A. Effects of Quercetin-Loaded Nanoparticles on MCF-7 Human Breast Cancer Cells. *Medicina* **2019**, *55*, 114. [CrossRef]
50. Chou, C.C.; Yang, J.S.; Lu, H.F.; Ip, S.W.; Lo, C.; Wu, C.C.; Lin, J.P.; Tang, N.Y.; Chung, J.G.; Chou, M.J.; et al. Quercetin-mediated cell cycle arrest and apoptosis involving activation of a caspase cascade through the mitochondrial pathway in human breast cancer MCF-7 cells. *Arch. Pharm. Res.* 2010, 33, 1181–1191. [CrossRef]

51. Chien, S.Y.; Wu, Y.C.; Chung, J.G.; Yang, J.S.; Lu, H.F.; Tsou, M.F.; Wood, W.; Kuo, S.J.; Chen, D.R. Quercetin-induced apoptosis acts through mitochondrial- and caspase-3-dependent pathways in human breast cancer MDA-MB-231 cells. *Hum. Exp. Toxicol.* 2009, 28, 493–503. [CrossRef]

52. Balakrishnan, S.; Mukherjee, S.; Das, S.; Bhat, F.A.; Raja Singh, P.; Patra, C.R.; Arunakaran, J. Gold nanoparticles–conjugated quercetin induces apoptosis via inhibition of EGFR/PKB/Akt–mediated pathway in breast cancer cell lines (MCF-7 and MDA-MB-231). *Cell Biochem. Funct.* 2017, 35, 217–231. [CrossRef] [PubMed]

53. Lin, C.W.; Hou, W.C.; Shen, S.C.; Juan, S.H.; Ko, C.H.; Wang, L.M.; Chen, Y.C. Quercetin inhibition of tumor invasion via suppressing PKCζ/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. *Carcinogenesis* 2008, 29, 1807–1815. [CrossRef] [PubMed]

54. Li, J.; Zhu, F.; Lubet, R.A.; De Luca, A.; Grubbs, C.; Ericson, M.E.; D’Alessio, A.; Normanno, N.; Dong, Z.; Bode, A.M. Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G2/M arrest and apoptosis. *Mol. Carcinog.* 2013, 52, 134–143. [CrossRef] [PubMed]

55. Khorsandi, L.; Orazizadeh, M.; Niazvand, F.; Abbaspour, M.R.; Mansouri, E.; Khodadadi, A. Quercetin induces apoptosis and necroptosis in MCF-7 breast cancer cells. *Bratislava Med. J.* 2017, 118, 123–128. [CrossRef] [PubMed]

56. Hu, J.; Zhang, Y.; Jiang, X.; Zhang, H.; Gao, Z.; Li, Y.; Fu, R.; Li, L.; Li, J.; Cui, H.; et al. ROS-mediated activation and mitochondrial translocation of CaMKII contributes to Drp1-dependent mitochondrial fission and apoptosis in triple-negative breast cancer cells by isorhamnetin and chloroquine. *J. Exp. Clin. Cancer Res.* 2019, 38, 1–16. [CrossRef]

57. Qiu, J.; Zhang, T.; Zhu, X.; Yang, C.; Wang, Y.; Zhou, N.; Ju, B.; Zhou, T.; Deng, G.; Qiu, C. Hyperoside induces breast cancer cells apoptosis via ROS-mediated NF-kB signaling pathway. *Int. J. Mol. Sci.* 2020, 21, 131. [CrossRef]

58. Steiner, J.L.; Davis, J.M.; McClellan, J.L.; Enos, R.T.; Carson, J.A.; Fayad, R.; Nagarkatti, M.; Nagarkatti, P.S.; Altomare, D.; Creek, K.E.; et al. Dose-dependent benefits of quercetin on tumorigenesis in the C3(1)/SV40Tag transgenic mouse model of breast cancer. *Cancer Biol. Ther.* 2014, 15, 1456–1467. [CrossRef]

59. Phromnoi, K.; Yodkeeree, S.; Anuchapreeda, S.; Limtrakul, P. Inhibition of MMP-3 activity and invasion of the MDA-MB-231 human invasive breast carcinoma cell line by bioflavonoids. *Acta Pharmacol. Sin.* 2009, 30, 1169–1176. [CrossRef]

60. Li, C.; Yang, D.; Zhao, Y.; Qiu, Y.; Cao, X.; Yu, Y.; Guo, H.; Gu, X.; Yin, X. Inhibitory Effects of Isorhamnetin on the Invasion of Human Breast Carcinoma Cells by Downregulating the Expression and Activity of Matrix Metalloproteinase-2/9. *Nutr. Cancer* 2015, 67, 1191–1200. [CrossRef]

61. Balakrishnan, S.; Bhat, F.A.; Raja Singh, P.; Mukherjee, S.; Elumalai, P.; Das, S.; Patra, C.R.; Arunakaran, J. Gold nanoparticle–conjugated quercetin inhibits epithelial–mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2-mediated pathway in breast cancer. *Cell Prolif.* 2016, 49, 678–697. [CrossRef]

62. Oh, S.J.; Kim, O.; Lee, J.S.; Kim, J.A.; Kim, M.R.; Choi, H.S.; Shim, J.H.; Kang, K.W.; Kim, Y.C. Inhibition of angiogenesis by quercetin in tamoxifen-resistant breast cancer cells. *Funct. Chem. Toxicol.* 2010, 48, 3227–3234. [CrossRef] [PubMed]

63. Brusselmans, K.; Vrolix, R.; Verhoeven, G.; Swinnen, J.V. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. *J. Biol. Chem.* 2005, 280, 5636–5645. [CrossRef] [PubMed]

64. Hanikoglu, A.; Kucuksayan, E.; Hanikoglu, F.; Ozben, T.; Menounou, G.; Sansone, A.; Chatgilialoglu, C.; Di Bella, G.; Ferreri, C. Effects of somatostatin, curcumin, and quercetin on the fatty acid profile of breast cancer cell membranes. *Can. J. Physiol. Pharmacol.* 2020, 98, 131–138. [CrossRef] [PubMed]

65. Kuiper, G.G.J.M.; Lemmen, J.G.; Carlsson, B.; Corton, J.C.; Safe, S.H.; Van Der Saag, P.T.; Van Der Burg, B.; Gustafsson, J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. *Endocrinology* 1998, 139, 4252–4263. [CrossRef] [PubMed]

66. Hung, H. Inhibition of Estrogen Receptor Alpha Expression and Function in MCF-7 Cells by Kaempferol. *J. Cell. Physiol.* 2004, 198, 197–208. [CrossRef] [PubMed]
67. Yiğitaslan, S.; Erol, K.; Özatik, F.Y.; Özatik, O.; Şahin, S.; Çengelli, Ç. Estrogen-like activity of quercetin in female rats. *Ercyes Tip Derg.* 2016, 38, 53–58. [CrossRef]  
68. Puranik, N.V.; Srivastava, P.; Bhatt, G.; John Mary, D.J.S.; Limaye, A.M.; Sivaraman, J. Determination and analysis of agonist and antagonist potential of naturally occurring flavonoids for estrogen receptor (ERs) by various parameters and molecular modelling approach. *Sci. Rep.* 2019, 9, 1–11. [CrossRef] [PubMed]  
69. Park, Y.J.; Choo, W.H.; Kim, H.R.; Chung, K.H.; Oh, S.M. Inhibitory aromatase effects of flavonoids from ginkgo biloba extracts on estrogen biosynthesis. *Asian Pac. J. Cancer Prev.* 2015, 16, 6317–6325. [CrossRef]  
70. Kao, Y.C.; Zhou, C.; Sherman, M.; Laughton, C.A.; Chen, S. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study. *Environ. Health Perspect.* 1998, 106, 85–92. [CrossRef]  
71. van Meeuwen, J.A.; ter Burg, W.; Piersma, A.H.; van den Berg, M.; Sanderson, J.T. Mixture effects of estrogenic compounds on proliferation and pS2 expression of MCF-7 human breast cancer cells. *Food Chem. Toxicol.* 2007, 45, 2319–2330. [CrossRef]  
72. Resende, F.A.; de Oliveira, A.P.S.; de Camargo, M.S.; Vilegas, W.; Varanda, E.A. Evaluation of Estrogenic Potential of Flavonoids Using a Recombinant Yeast Strain and MCF7/Bus Cell Proliferation Assay. *PLoS ONE* 2013, 8, 1–7. [CrossRef] [PubMed]  
73. Seung, M.O.; Yeon, P.K.; Kyu, H.C. Biphasic effects of kaempferol on the estrogenicity in human breast cancer cells. *Arch. Pharm. Res.* 2006, 29, 354–362.  
74. Kim, S.H.; Hwang, K.A.; Choi, K.C. Treatment with kaempferol suppresses breast cancer cell growth caused by estrogen and triclosan in cellular and xenograft breast cancer models. *J. Nutr. Biochem.* 2016, 28, 70–82. [CrossRef] [PubMed]  
75. Lee, G.A.; Choi, K.C.; Hwang, K.A. Treatment with phytoestrogens reversed triclosan and bisphenol A-induced anti-apoptosis in breast cancer cells. *Biomed. Ther.* 2018, 26, 503–511. [CrossRef] [PubMed]  
76. Lee, G.A.; Choi, K.C.; Hwang, K.A. Kaempferol, a phytoestrogen, suppressed triclosan-induced epithelial-mesenchymal transition and metastatic-related behaviors of MCF-7 breast cancer cells. *Environ. Toxicol. Pharmacol.* 2017, 49, 48–57. [CrossRef] [PubMed]  
77. Mei, Y.Q.; Kai, L.; Qun, S.; Qingyue, L.; Jinghui, H.; Fangxuan, H.; Ren-Wang, J. Reversal of multidrug resistance in cancer by multi-functional flavonoids. *Front. Oncol.* 2019, 9, 487.  
78. Soo, Y.C.; Min, K.S.; Na, H.K.; Jung, O.J.; Eun, J.G.; Hwa, J.L. Inhibition of P-glycoprotein by natural products against human breast cancer cells. *Arch. Pharm. Res.* 2005, 28, 823–828.  
79. Li, S.; Zhao, Q.; Wang, B.; Wang, X.; Li, K. Quercetin enhances chemotherapeutic effects of doxorubicin against human breast cancer cells while reducing toxic side effects of it. *Biomed. Pharmacother.* 2018, 100, 441–447. [CrossRef]  
80. Li, S.; Zhao, Q.; Wang, B.; Yuan, S.; Wang, X.; Li, K. Quercetin reversed MDR in breast cancer cells through down-regulating P-gp expression and eliminating cancer stem cells mediated by YB-1 nuclear translocation. *Phyther. Res.* 2018, 32, 1530–1536. [CrossRef]  
81. Desale, J.P.; Swami, R.; Kushwah, V.; Katiyar, S.S.; Jain, S. Chemosensitizer and docetaxel-loaded albumin nanoparticle: Overcoming drug resistance and improving therapeutic efficacy. *Nanomedicine* 2018, 13, 2759–2776. [CrossRef]  
82. Kumar, M.; Sharma, G.; Misra, C.; Kumar, R.; Singh, B.; Kataria, O.P.; Raza, K. N-desmethyl tamoxifen and quercetin-loaded multiwalled CNFs: A synergistic approach to overcome MDR in cancer cells. *Mater. Sci. Eng. C* 2018, 89, 274–282. [CrossRef] [PubMed]  
83. Imai, Y.; Tsukahara, S.; Asada, S.; Sugimoto, Y. Phytoestrogens/flavonoids reverse breast cancer resistance protein/Abcg2-mediated multidrug resistance. *Cancer Res.* 2004, 64, 4346–4352. [CrossRef] [PubMed]  
84. Fan, X.; Bai, J.; Zhao, S.; Hu, M.; Sun, Y.; Wang, B.; Ji, M.; Jin, J.; Wang, X.; Hu, J.; et al. Evaluation of inhibitory effects of flavonoids on breast cancer resistance protein (BCRP): From library screening to biological evaluation to structure-activity relationship. *Toxicol. Vitru.* 2019, 61, 104642. [CrossRef] [PubMed]  
85. An, G.; Gallegos, J.; Morris, M.E. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. *Drug Metab. Dispos.* 2011, 39, 426–432. [CrossRef]  
86. Zheng, L.; Zhu, L.; Zhao, M.; Shi, J.; Li, Y.; Yu, J.; Jiang, H.; Wu, J.; Tong, Y.; Liu, Y.; et al. In Vivo Exposure of Kaempferol Is Driven by Phase II Metabolic Enzymes and Efflux Transporters. *AAPS J.* 2016, 18, 1289–1299. [CrossRef]
87. Li, Y.; Lu, L.; Wang, L.; Qu, W.; Liu, W.; Xie, Y.; Zheng, H.; Wang, Y.; Qi, X.; Hu, M.; et al. Interplay of Efflux Transporters with Glucuronidation and Its Impact on Subcellular Aglycone and Glucuronide Disposition: A Case Study with Kaempferol. *Mol. Pharm.* **2018**, *15*, 5602–5614. [CrossRef]

88. Yao, L.H.; Jiang, Y.M.; Shi, J.; Tomás-Barberán, F.A.; Datta, N.; Singanusong, R.; Chen, S.S. Flavonoids in food and their health benefits. *Plant Foods Hum. Nutr.* **2004**, *59*, 113–122. [CrossRef]

89. Pastrana-Bonilla, E.; Akoh, C.C.; Sellappan, S.; Krewer, G. Phenolic Content and Antioxidant Capacity of Muscadine Grapes. *J. Agric. Food Chem.* **2003**, *51*, 5497–5503. [CrossRef]

90. Graham, H.N. Green tea composition, consumption, and polyphenol chemistry. *Prev. Med.* **1992**, *21*, 334–350. [CrossRef]

91. Bell, J.R.C.; Donovan, J.L.; Wong, R.; Waterhouse, A.L.; German, J.B.; Walzem, R.L. (+)-Catechin in human plasma after ingestion of a single serving of reconstituted red wine. *Am. J. Clin. Nutr.* **2000**, *71*, 103–108. [CrossRef]

92. Silva, J.M.R.; Rigaud, J.; Cheynier, V.; Cheminat, A.; Moutounet, M. Procyanidin dimers and trimers from grape seeds. *Phytochemistry* **1991**, *30*, 1259–1264. [CrossRef]

93. Prieur, C.; Rigaud, J.; Cheynier, V.; Moutounet, M. Oligomeric and polymeric procyanidins from grape seeds. *Phytochemistry* **1994**, *36*, 781–784. [CrossRef]

94. Kim, H.; Hall, P.; Smith, M.; Kirk, M.; Prasain, J.K.; Barnes, S.; Grubbs, C. Chemoprevention by Grape Seed Extract and Genistein in Carcinogen-induced Mammary Cancer in Rats Is Diet Dependent 1, 2. *Int. Res. Conf. Food Nutr. Cancer* **2004**, 3445–3452. [CrossRef] [PubMed]

95. Ou, K.; Gu, L. Absorption and metabolism of proanthocyanidins. *J. Funct. Foods* **2014**, *7*, 43–53. [CrossRef]

96. Tsang, C.; Auger, C.; Mullen, W.; Borton, A.; Rouanet, J.-M.; Crozier, A.; Teissedre, P.-L. The absorption, metabolism and excretion of flavan-3-ols and procyanidins following the ingestion of a grape seed extract by rats. *Br. J. Nutr.* **2005**, *94*, 170–181. [CrossRef]

97. Serra, A.; Macl, A.; Romero, M.P.; Valls, J.; Bladé, C.; Arola, L.; Motilva, M.J. Bioavailability of procyanidin dimers and trimers and matrix food effects in in vitro and in vivo models. *Br. J. Nutr.* **2010**, *103*, 944–952. [CrossRef]

98. Sano, A.; Yamakoshi, J.; Tokutake, S.; Tobe, K.; Kubota, Y.; Kikuchi, M. Procyanidin B1 is detected in human serum after intake of proanthocyanidin-rich grape seed extract. *Biosci. Biotechnol. Biochem.* **2003**, *67*, 1140–1143. [CrossRef]

99. Yang, C.S.; Sang, S.; lambert, J.D.; Lee, M.J. Bioavailability issues in studying the health effects of plant polyphenolic compounds. *Mol. Nutr. Food Res.* **2008**, *52*, 139–151. [CrossRef]

100. Meng, X.; Sang, S.; Zhu, N.; Lu, H.; Sheng, S.; Lee, M.J.; Ho, C.T.; Yang, C.S. Identification and characterization of methylated and ring-fission metabolites of tea catechins formed in humans, mice, and rats. *Chem. Res. Toxicol.* **2002**, *15*, 1042–1050. [CrossRef]

101. Faria, A.; Calhau, C.; De Freitas, V.; Mateus, N. Procyanidins as antioxidants and tumor cell growth modulators. *J. Agric. Food Chem.* **2006**, *54*, 2392–2397. [CrossRef]

102. Alshatwi, A.A. Catechin hydrate suppresses MCF-7 proliferation through TP53/Caspase-mediated apoptosis. *J. Exp. Clin. Cancer Res.* **2010**, *29*, 1–9. [CrossRef] [PubMed]

103. Damianaki, A.; Bakogeorgou, E.; Kampa, M.; Notas, G.; Hatzoglou, A.; Panagiotou, S.; Gemetzi, C.; Kouroumalis, E.; Martin, P.M.; Castanas, E. Potent inhibitory action of red wine polyphenols on human breast cancer cells. *J. Cell. Biochem.* **2000**, *78*, 429–441. [CrossRef]

104. Singletary, K.W.; Moline, B. Effect of Grape Seed Proanthocyanidins on Colon Aberrant Crypts and Breast Tumors in a Rat Dual-Organ Tumor Model. *Nutr. Cancer* **2001**, *39*, 252–258. [CrossRef] [PubMed]

105. Wahner-roedler, D.L.; Bauer, B.A.; Loehrer, L.L.; Cha, S.S.; vera, J.; Hoskin, T.L.; Olson, J.E. The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women—A Pilot Study. *J. Diet. Suppl.* **2016**, *11*, 184–197. [CrossRef]

106. Ye, X.; Krohn, R.L.; Liu, W.; Joshi, S.S.; Kusznynski, C.A.; McGinn, T.R.; Bagchi, M.; Preuss, H.G.; Stohs, S.J.; Bagchi, D. The cytotoxic effects of a novel IH636 grape seed proanthocyanidin extract on cultured human cancer cells. *Stress Adapt. Prophyl. Treat.* **1999**, *196*, 99–108.

107. Brooker, S.; Martin, S.; Pearson, A.; Bagchi, D.; Earl, J.; Gothard, L.; Hall, E.; Porter, L.; Yarnold, J. Double-blind, placebo-controlled, randomised phase II trial of IH636 grape seed proanthocyanidin extract (GSPE) in patients with radiation-induced breast induration. *Radiother. Oncol.* **2006**, *79*, 45–51. [CrossRef]
10. Afq, F.; Zaman, N.; Khan, N.; Syed, D.N.; Sarfaraz, S.; Zaid, M.A.; Mukhtar, H. Inhibition of epidermal growth factor receptor signaling pathway by delphinidin, an anthocyanidin in pigmented fruits and vegetables. *Int. J. Cancer* 2008, 123, 1508–1515. [CrossRef]

11. Abd El-Rehim, D.M.; Pinder, S.E.; Paish, C.E.; Bell, J.A.; Rampaul, R.S.; Blamey, R.W.; Robertson, J.F.R.; Nicholson, R.I.; Ellis, I.O. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. *Br. J. Cancer* 2004, 91, 1532–1542. [CrossRef]

12. Chen, J.; Zhu, Y.; Zhang, W.; Peng, X.; Zhou, J.; Li, F.; Han, B.; Liu, X.; Ou, Y.; Yu, X. Delphinidin induced protective autophagy via mTOR pathway suppression and AMPK pathway activation in HER-2 positive breast cancer cells. *BMC Cancer* 2018, 18, 342. [CrossRef] [PubMed]

13. Ma, X.; Ning, S. Cyanidin-3-glucoside attenuates the angiogenesis of breast cancer via inhibiting STAT3/VEGF pathway. *Phyther. Res.* 2019, 33, 81–89. [CrossRef] [PubMed]

14. Liang, L.; Liu, X.; He, J.; Shao, Y.; Liu, J.; Wang, Z.; Xia, L.; Han, T.; Wu, P. Cyanidin-3-glucoside induces mesenchymal to epithelial transition via activating Sirt1 expression in triple negative breast cancer cells. *Biochimie* 2019, 162, 107–115. [CrossRef] [PubMed]

15. Samavat, H.; Kurzer, M.S. Estrogen Metabolism and Breast Cancer. *Cancer Lett.* 2015, 356, 231–243. [CrossRef] [PubMed]

16. Reis-Filho, J.S.; Tutt, A.N.J. Triple negative tumours: A critical review. *Histopathology* 2008, 52, 108–118. [CrossRef]

17. Zhang, X.T.; Kang, L.G.; Ding, L.; Vranic, S.; Gatalica, Z.; Wang, Z.Y. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. *Oncogene* 2011, 30, 770. [CrossRef]

18. Wang, Z.Y.; Zhang, X.T.; Shen, P.; Loggie, B.W.; Chang, Y.C.; Deuel, T.F. A variant of estrogen receptor-α, hER-α36: Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. *Proc. Natl. Acad. Sci. USA* 2006, 103, 9063–9068. [CrossRef]

19. Wang, L.; Li, H.; Yang, S.; Ma, W.; Liu, M.; Guo, S.; Zhan, J.; Zhang, H.; Tsang, S.Y.; Zhang, Z.; et al. Cyanidin-3-α-glucoside directly binds to ERα36 and inhibits EGFR-positive triple-negative breast cancer. *Oncotarget* 2016, 7, 68864. [CrossRef]

20. Fernandes, I.; Faria, A.; Azevedo, J.; Soares, S.; Calhau, C.; De Freitas, V.; Mateus, N. Influence of anthocyanins, derivative pigments and other catechol and pyrogallol-type phenolics on breast cancer cell proliferation. *J. Agric. Food Chem.* 2010, 58, 3785–3792. [CrossRef]

21. Swain, S.M.; Baselga, J.; Kim, S.B.; Ro, J.; Semiglazov, V.; Campone, M.; Ciruelos, E.; Ferrero, J.; Schneeweiss, A.; Heeson, S.; et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *N. Engl. J. Med.* 2015, 372, 724–734. [CrossRef]

22. Witzel, I.; Müller, V.; Abenhardt, W.; Kaufmann, M.; Schoenegg, W.; Schneeweis, A.; Jänicke, F. Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer—Results from the HER-OS patient registry. *BMC Cancer* 2014, 14, 806. [CrossRef] [PubMed]

23. Li, X.; Xu, J.; Tang, X.; Liu, Y.; Yu, X.; Wang, Z.; Liu, W. Anthocyanins inhibit trastuzumab-resistant breast cancer in vitro and in vivo. *Mol. Med. Rep.* 2016, 13, 4007–4013. [CrossRef] [PubMed]

24. Liu, W.; Xu, J.; Liu, Y.; Yu, X.; Tang, X.; Wang, Z.; Li, X. Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2-positive breast cancer cells in vitro and in vivo. *Mol. Med. Rep.* 2014, 10, 1921–1926. [CrossRef] [PubMed]

25. Shen, T.; Wang, X.N.; Lou, H.X. Natural stilbenes: An overview. *Nat. Prod. Rep.* 2009, 26, 916–935. [CrossRef]

26. Signorelli, P.; Ghidoni, R. Resveratrol as an anticancer nutrient: Molecular basis, open questions and promises. *J. Nutr. Biochem.* 2005, 16, 449–466. [CrossRef]

27. Langcake, P.; Pryce, R.J. The production of resveratrol by *Vitis vinifera* and other members of the Vitaceae as a response to infection or injury. *Physiol. Plant Pathol.* 1976, 9, 77–86. [CrossRef]

28. Jeandet, P.; Bessis, R.; Gautheron, B. The production of resveratrol (3, 5, 4′-trihydroxystilbene) by grape berries in different developmental stages. *Am. J. Enol. Vitic.* 1991, 42, 41–46.

29. Goldberg, D.M.; Yan, J.; Ng, E.; Diamandis, E.P.; Karumanchi, A.; Soleas, G.; Waterhouse, A.L. A global survey of trans-resveratrol concentrations in commercial wines. *Am. J. Enol. Vitic.* 1995, 46, 159–165.

30. Romero-Pérez, A.I.; Lamuela-Raventós, R.M.; Waterhouse, A.L.; De La Torre-Boronat, M.C. Levels of cis- and trans-Resveratrol and Their Glucosides in White and Rosé Vitis vinifera Wines from Spain. *J. Agric. Food Chem.* 1996, 44, 2124–2128. [CrossRef]
151. Pace-Asciak, C.; Rounova, O.; Hahn, S.E.; Diamandis, E.P.; Goldberg, D.M. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. *Clin. Chim. Acta* **1996**, *246*, 163–182. [CrossRef]

152. Weiskirchen, S.; Weiskirchen, R. Resveratrol: How Much Wine Do You Have to Drink to Stay Healthy? *Adv. Nutr. An Int. Rev. J.* **2016**, *7*, 706–718. [CrossRef] [PubMed]

153. Goldberg, D.M.; Yan, J.; Soleas, G.J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. *Clin. Biochem.* **2003**, *36*, 79–87. [CrossRef]

154. Walle, T. Bioavailability of resveratrol. *Ann. N. Y. Acad. Sci.* **2011**, *1215*, 9–15. [CrossRef] [PubMed]

155. Sinha, D.; Sarkar, N.; Biswas, J.; Bishayee, A. Resveratrol for breast cancer prevention and therapy: Preclinical evidence and molecular mechanisms. *Semin. Cancer Biol.* **2016**, *40*, 209–232. [CrossRef] [PubMed]

156. Chimento, A.; De Amicis, F.; Sirianni, R.; Sinicropi, M.S.; Puoci, F.; Casaburi, I.; Saturnino, C.; Pezzi, V. Chakraborty, S.; Levenson, A.S.; Biswas, P.K. Structural insights into Resveratrol’s antagonist and partial agonist actions on estrogen receptors: a promising molecular target. *J. Steroid Biochem. Mol. Biol.* **2019**, *2017*, 3657–3667. [CrossRef] [PubMed]

157. Nawaz, W.; Zhou, Z.; Deng, S.; Ma, X.; Ma, X.; Li, C.; Shu, X. Therapeutic versatility of resveratrol derivatives. *Nutrients* **2017**, *9*, 1188. [CrossRef] [PubMed]

158. da Costa, D.C.F.; Filhalho, E.; Silva, J.L. Cancer chemoprevention by resveratrol: The P53 tumor suppressor protein as a promising molecular target. *Molecules* **2017**, *22*, 1014. [CrossRef]

159. Jang, M.; Cai, L.; Udeani, G.O.; Slowing, K.V.; Thomas, C.F.; Beecher, C.W.W.; Fong, H.H.S.; Farnsworth, N.R.; Kinghorn, A.D.; Mehta, R.G.; et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. *Science* **1997**, *275*, 218–220. [CrossRef]

160. Pezzuto, J.M. Resveratrol: Twenty years of growth, development and controversy. *Biomol. Ther.* **2019**, *27*, 1. [CrossRef]

161. Casanova, F.; Quarti, J.; Da Costa, D.C.F.; Ramos, C.A.; Da Silva, J.L.; Filhalho, E. Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest. *J. Cell. Physiol.* **2016**, *231*, 888–899. [CrossRef] [PubMed]

162. Varoni, E.M.; Lo Faro, A.F.; Sharifi-Rad, J.; Iriti, M. Anticancer Molecular Mechanisms of Resveratrol. *Front. Nutr.* **2016**, *3*, 8. [CrossRef] [PubMed]

163. Ko, J.H.; Sethi, G.; Um, J.Y.; Shamnugam, M.K.; Arfuso, F.; Kumar, A.P.; Bishayee, A.; Ahn, K.S. The role of resveratrol in cancer therapy. *Int. J. Mol. Sci.* **2017**, *18*, 2589. [CrossRef] [PubMed]

164. Ndiaye, M.; Kumar, R.; Ahmad, N. Resveratrol in cancer management: Where are we and where do we go from here? *Ann. N. Y. Acad. Sci.* **2011**, *1215*, 144–149. [CrossRef] [PubMed]

165. Levi, F.; Pasche, C.; Lucchini, F.; Ghidoni, R.; Ferraroni, M.; La Vecchia, C. Resveratrol and breast cancer risk. *Eur. J. Cancer Prev.* **2005**, *14*, 139–142. [CrossRef] [PubMed]

166. Chakraborty, S.; Levenson, A.S.; Biswas, P.K. Structural insights into Resveratrol’s antagonist and partial agonist actions on estrogen receptor alpha. *BMC Struct. Biol.* **2013**, *13*, 27. [CrossRef]

167. Poschner, S.; Maier-Salamon, A.; Thalhammer, T.; Jäger, W. Resveratrol and other dietary polyphenols are inhibitors of estrogen metabolism in human breast cancer cells. *J. Steroid Biochem. Mol. Biol.* **2019**, *190*, 11–18. [CrossRef]

168. Jordan, V.C. Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents. *J. Med. Chem.* **2003**, *46*, 1081–1111. [CrossRef]

169. Gehm, B.D.; McAndrews, J.M.; Chien, P.Y.; Jameson, J.L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 14138–14143. [CrossRef]

170. Levenson, A.S.; Gehm, B.D.; Pearce, S.T.; Horiguchi, J.; Simons, L.A.; Ward, J.E.; Jameson, J.L.; Jordan, V.C. Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ERα. *Int. J. Cancer* **2003**, *104*, 587–596. [CrossRef]

171. Lu, R.; Serrero, G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. *J. Cell. Physiol.* **1999**, *179*, 297–304. [CrossRef]

172. Bowers, J.L.; Tyulmenkov, V.V.; Jernigan, S.C.; Klinge, C.M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors α and β. *Endocrinology* **2000**, *141*, 3657–3667. [CrossRef] [PubMed]

173. Gehm, B.D.; Levenson, A.S.; Liu, H.; Lee, E.J.; Amundsen, B.M.; Cushman, M.; Jordan, V.C.; Jameson, J.L. Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: Role of AF-1 and AF-2. *J. Steroid Biochem. Mol. Biol.* **2004**, *88*, 223–234. [CrossRef] [PubMed]
174. Simpson, E.R.; Michael, M.D.; Agarwal, V.R.; Hinshelwood, M.M.; Bulun, S.E.; Zhao, Y. Cytochromes P450 11: Expression of the CYP19 (aromatase) gene: An unusual case of alternative promoter usage. *FASEB J.* 1997, 11, 29–36. [CrossRef]

175. Wang, Y.; Lee, K.W.; Chan, E.L.; Chen, S.; Leung, L.K. The red wine polyphenol resveratrol displays bilevel inhibition on aromatase in breast cancer cells. *Toxicol. Sci.* 2006, 92, 71–77. [CrossRef]

176. Chottanapund, S.; Van Duursen, M.B.M.; Navasumrit, P.; Hunsonti, P.; Timtavorn, S.; Ruchirawat, M.; Van den Berg, M. Anti-aromatase effect of resveratrol and melatonin on hormonal positive breast cancer cells co-cultured with breast adipose fibroblasts. *Toxicol. In Vitro* 2014, 28, 1215–1221. [CrossRef]

177. Le Corre, L.; Chalabi, N.; Delort, L.; Bignon, Y.J.; Bernard-Gallon, D.J. Resveratrol and breast cancer. *Molecules* 2020, 1, 77. [CrossRef]

178. Simpson, E.R.; Michael, M.D.; Agarwal, V.R.; Hinshelwood, M.M.; Bulun, S.E.; Zhao, Y. Cytochromes P450. *Molecules* 2005, 10, 462–471. [CrossRef] [PubMed]

179. Sinha, R.; Caporaso, N. Diet, Genetic Susceptibility and Human Etiology. *J. Nutr.* 1999, 129, 5565–5595. [CrossRef]

180. Da Costa, D.C.F.; Casanova, F.A.; Quarti, J.; Malheiros, M.S.; Sanches, D.; dos Santos, P.S.; Fialho, E.; Silva, J.L. Transient Transfection of a Wild-Type p53 Gene Triggers Resveratrol-Induced Apoptosis in Cancer Cells. *PLoS ONE* 2012, 7, 1–12. [CrossRef]

181. Da Costa, D.C.F.; Casanova, F.A.; Quarti, J.; Malheiros, M.S.; Sanches, D.; dos Santos, P.S.; Fialho, E.; Silva, J.L. Transient Transfection of a Wild-Type p53 Gene Triggers Resveratrol-Induced Apoptosis in Cancer Cells. *PLoS ONE* 2012, 7, 1–12. [CrossRef]

182. Chang, L.C.; Yu, Y.L. Dietary components as epigenetic-regulating agents against cancer. *Biomedicine* 2016, 6, 1–8. [CrossRef]

183. Alamolhodaei, N.S.; Tsatsakis, A.M.; Ramezani, M.; Hayes, A.W.; Karimi, G. Resveratrol as MDR reversion molecule in breast cancer: An overview. *Food Chem. Toxicol.* 2017, 103, 223–232. [CrossRef] [PubMed]

184. Singh, C.K.; George, J.; Ahmad, N. Resveratrol-based combinatorial strategies for cancer management. *Ann. N. Y. Acad. Sci.* 2014, 1290, 113–121. [CrossRef] [PubMed]

185. Chow, H.H.S.; Garland, L.L.; Heckman-Stoddard, B.M.; Hsu, C.H.; Butler, V.D.; Cordova, C.A.; Chew, W.M.; Cornelison, T.L. A pilot clinical study of resveratrol in postmenopausal women with high body mass index: Effects on systemic sex steroid hormones. *J. Transl. Med.* 2014, 12, 1–7. [CrossRef]

186. Fernandes, I.; Pérez-Gregorio, R.; Soares, S.; Mateus, N.; De Freitas, V.; Santos-Buelga, C.; Feliciano, A.S. Wine flavonoids in health and disease prevention. *Molecules* 2017, 22, 292. [CrossRef] [PubMed]

187. Arbulu, M.; Sampedro, M.C.; Gómez-Caballero, A.; Goicolea, M.A.; Barrio, R.J. Untargeted metabolomic analysis using liquid chromatography quadrupole time-of-flight mass spectrometry for non-volatile profiling of wines. *Anal. Chim. Acta* 2015, 858, 32–41. [CrossRef] [PubMed]

188. Alves Filho, E.G.; Silva, L.M.A.; Ribeiro, P.R.V.; de Brito, E.S.; Zocolo, G.J.; Souza-Leão, P.C.; Marques, A.T.B.; Quintela, A.L.; Larsen, F.H.; Canuto, K.M. 1 H NMR and LC-MS-based metabolomic approach for evaluation of the seasonality and viticultural practices in wines from São Francisco River Valley, a Brazilian semi-arid region. *Food Chem.* 2019, 289, 558–567. [CrossRef] [PubMed]

189. Cassino, C.; Tsolakis, C.; Bonello, F.; Gianotti, V.; Osella, D. Wine evolution during bottle aging, studied by 1H NMR spectroscopy and multivariate statistical analysis. *Food Res. Int.* 2019, 116, 566–577. [CrossRef]

190. Forester, S.C.; Waterhouse, A.L. Metabolites Are Key to Understanding Health Effects of Wine Polyphenolics. *J. Nutr.* 2009, 139, 18245–18315. [CrossRef]

191. Jiménez-Girón, A.; Queipo-Ortuño, M.; Boto-Ordoñez, M.; Muñoz-Gonzáles, I.; Sánchez-Patán, F.; Monagas, M.; Martín-Álvarez, P.; Murri, M.; Tínaheos, J.F.; Abdres-Lacueva, C.; et al. Comparative Study of Microbial-Derived Phenolic Metabolites in Human Feces after Intake of Gin, Red Wine, and Dealcoholized Red Wine. *J. Agric. Food Chem.* 2013, 61, 3909–3915. [CrossRef]

192. Jiménez-Girón, A.; Ibáñez, C.; Cifuentes, A.; Simó, C.; Muñoz-Gonzáles, I.; Martín-Álvarez, P.J.; Bartolomé, B.; Moreno-Arribas, M.V. Faecal metabolomic fingerprint after moderate consumption of red wine by healthy subjects. *J. Proteome Res.* 2015, 14, 897–905. [CrossRef] [PubMed]
193. Gonthier, M.-P.; Cheynier, V.; Donovan, J.L.; Manach, C.; Morand, C.; Mila, I.; Lapierre, C.; Rémyès, C.; Scalbert, A. Microbial Aromatic Acid Metabolites Formed in the Gut Account for a Major Fraction of the Polyphenols Excreted in Urine of Rats Fed Red Wine Polyphenols. J. Nutr. 2003, 133, 461–467. [CrossRef] [PubMed]

194. Al Ali, S.H.H.; Al-Qubaisi, M.; Hussein, M.Z.; Ismail, M.; Bullo, S. Hippuric acid nanocomposite enhances doxorubicin and oxaliplatin-induced cytotoxicity in MDA-MB231, MCF-7 and Caco2 cell lines. Drug Des. Devel. Ther. 2013, 7, 25. [CrossRef]

195. Wang, X.N.; Wang, K.Y.; Zhang, X.S.; Yang, C.; Li, X.Y. 4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2/p53 pathway. Biochim. Biophys. Res. Commun. 2018, 504, 812–819. [CrossRef] [PubMed]

196. Yin, M.C.; Lin, C.C.; Wu, H.C.; Tsao, S.M.; Hsu, C.K. Apoptotic effects of protocatechuic acid in human breast, lung, liver, cervix, and prostate cancer cells: Potential mechanisms of action. J. Agric. Food Chem. 2009, 57, 6468–6473. [CrossRef]

197. Henry-Vitrac, C.; Desmoulière, A.; Girard, D.; Méroullé, J.M.; Krisa, S. Transport, deglycosylation, and metabolism of trans-piceid by small intestinal epithelial cells. Eur. J. Nutr. 2006, 45, 376–382. [CrossRef]

198. Mennen, L.I.; Sapinho, D.; Ito, H.; Bertrais, S.; Galan, P.; Hercberg, S.; Scalbert, A. Urinary flavonoids: Estimation of flavonoid intake by human subjects after red wine consumption. Br. J. Nutr. 2009, 102, 1021–1035. [CrossRef]

199. Lee, H.I.; Lin, C.S.; Kao, S.H.; Chou, M.C. Gallic acid induces G1 phase arrest and apoptosis of triple-negative breast cancer cell MDA-MB-231 via p38 mitogen-activated protein kinase/p21/p27 axis. Anticancer Drugs 2017, 28, 1150–1156. [CrossRef]

200. Wang, K.; Zhu, X.; Zhang, K.; Zhu, L.; Zhou, F. Investigation of Gallic Acid Induced Anticancer Effect in Human Breast Carcinoma MCF-7 Cells. J. Biochem. Mol. Toxicol. 2014, 28, 387–393. [CrossRef]

201. Vitarione, P.; Sforza, S.; Del Rio, D. Occurrence, Bioavailability, and Metabolism of Resveratrol. In Flavonoids and Related Compounds: Bioavailability and Function, 1st ed.; Spencer, J.P.E., Crozier, A., Eds.; CRC Press: Boca Raton, FL, USA, 2012; pp. 167–182.

202. Henry-Vitrac, C.; Desmoulière, A.; Girard, D.; Méroullé, J.M.; Krissa, S. Transport, deglycosylation, and metabolism of trans-piceid by small intestinal epithelial cells. Eur. J. Nutr. 2006, 45, 376–382. [CrossRef]

203. Bode, L.M.; Bunzel, D.; Huch, M.; Cho, G.S.; Ruhland, D.; Bunzel, M.; Bub, A.; Franz, C.M.A.P.; Kulling, S.E. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am. J. Clin. Nutr. 2013, 97, 295–309. [CrossRef] [PubMed]

204. Lappano, R.; Rosano, C.; Madeo, A.; Albanito, L.; Plastina, P.; Gabriele, B.; Forti, L.; Stivala, L.A.; Iacopetta, D.; Dolce, V.; et al. Structure-activity relationships of resveratrol and derivatives in breast cancer cells. Mol. Nutr. Food Res. 2009, 53, 845–858. [CrossRef] [PubMed]

205. Ruotolo, R.; Calani, L.; Fietta, E.; Brighenti, F.; Crozier, A.; Meda, C.; Maggi, A.; Ottonello, S.; Del Rio, D. Anti-estrogenic activity of a human resveratrol metabolite. Nutr. Metab. Cardiovasc. Dis. 2013, 23, 1086–1092. [CrossRef] [PubMed]

206. Gakh, A.A.; Anisimova, N.Y.; Kiselevsky, M.V.; Sadovnikov, S.V.; Stankov, I.N.; Yudin, M.V.; Rufanov, K.A.; Krasavin, M.Y.; Sonnov, A.V. Dihydro-resveratrol—A potent dietary polyphenol. Bioorganic Med. Chem. Lett. 2010, 20, 6149–6151. [CrossRef]

207. Giménez-Bastida, J.A.; Ávila-Gálvez, M.A.; Espín, J.C.; González-Sarrias, A. Conjugated Physiological Resveratrol Metabolites Induce Senescence in Breast Cancer Cells: Role of p53/p21 and p16/Rb Pathways, and ABC Transporters. Mol. Nutr. Food Res. 2019, 63, 1900629. [CrossRef]

208. Donovan, J.L.; Crespy, V.; Manach, C.; Morand, C.; Besson, C.; Scalbert, A.; Rémyès, C. Catechin Is Metabolized by Both the Small Intestine and Liver of Rats. J. Nutr. 2001, 131, 1753–1757. [CrossRef]

209. Baba, S.; Osakabe, N.; Natsume, M.; Muto, Y.; Takizawa, T.; Terao, J. In Vivo Comparison of the Bioavailability of (+)-Catechin, (−)-Epicatechin and Their Mixture in Orally Administered Rats. J. Nutr. 2001, 131, 2885–2891. [CrossRef]

210. Donovan, J.L.; Kasim-Karakas, S.; German, J.B.; Waterhouse, A.L. Urinary excretion of catechin metabolites by human subjects after red wine consumption. Br. J. Nutr. 2002, 87, 31–37. [CrossRef]
211. Kim, D.H.; Jung, E.A.; Sohn, I.S.; Han, J.A.; Kim, T.H.; Han, M.J. Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. *Arch. Pharm. Res.* 1998, 21, 17–23. [CrossRef]

212. Fang, J. Bioavailability of anthocyanins. *Drug Metab. Rev.* 2014, 46, 508–520. [CrossRef] [PubMed]

213. Tsuda, T.; Horio, F.; Osawa, T. Absorption and metabolism of cyanidin 3-O-β-D-glucoside in rats. *FEBS Lett.* 1999, 449, 179–182. [CrossRef]

214. Olivas-Aguirre, F.J.; Rodrigo-García, J.; Martínez-Ruíz, N.D.R.; Cárdenas-Robles, A.I.; Mendoza-Díaz, S.O.; Álvarez-Parrilla, E.; González-Aguilar, G.A.; De La Rosa, L.A.; Ramos-Jíménez, A.; Wall-Medrano, A. Cyanidin-3-O-glucoside: Physical-chemistry, foodomics and health effects. *Molecules* 2016, 21, 1264. [CrossRef] [PubMed]

215. Bitsch, R.; Netz, M.; Frank, T.; Strass, G.; Bitsch, I. Bioavailability and biokinetics of anthocyanins from red grape juice and red wine. *J. Biomed. Biotechnol.* 2004, 2004, 293–298. [CrossRef]

216. Booth, A.N.; Murray, C.W.; Jones, F.T.; Deeds, F. The Metabolic Fate of Rutin and Quercetin in the Animal Body. *J. Biol. Chem.* 1956, 233, 251–257.

217. Gross, M.; Pfeiffer, M.; Martini, M.; Campbell, D.; Slavin, J.; Potter, J. The quantitation of metabolites of quercetin flavonols in human urine. *Cancer Epidemiol. Biomarkers Prev.* 1996, 5, 711–720. [PubMed]

218. Yamazaki, S.; Sakakibara, H.; Takemura, H.; Yasuda, M.; Shimo, K. Quercetin-3-O-glucuronide inhibits noradrenaline binding to α2-adrenergic receptor, thus suppressing DNA damage induced by treatment with 4-hydroxyestradiol and noradrenaline in MCF-10A cells. *J. Steroid Biochem. Mol. Biol.* 2014, 143, 122–129. [CrossRef] [PubMed]

219. Hadi, N.I.; Jamal, Q.; Iqbal, A.; Shaikh, F.; Somroo, S.; Musharraf, S.G. Serum Metabolomic Profiles for Breast Cancer Diagnosis, Grading and Staging by Gas Chromatography-Mass Spectrometry. *Sci. Rep.* 2017, 7, 1–11. [CrossRef]

220. Jovan, M.; Collado, R.; Quiles, J.L.; Ramírez-Tortosa, M.C.; Sol, J.; Ruiz-Sanjuan, M.; Fernandez, M.; Cabrera, C.d.l.T.; Ramírez-Tortosa, C.; Granados-Principal, S.; et al. A plasma metabolomic signature discloses human breast cancer. *Oncotarget* 2017, 8, 19522. [CrossRef]

221. Liu, H.; Liu, Y.; Zhang, J.T. A new mechanism of drug resistance in breast cancer cells: Fatty acid synthase overexpression-mediated palmitate overproduction. *Mol. Cancer Ther.* 2008, 7, 263–270. [CrossRef]
231. Wang, J.B.; Erickson, J.W.; Fuji, R.; Ramachandran, S.; Gao, P.; Dinavahi, R.; Wilson, K.F.; Ambrosio, A.L.B.; Dias, S.M.G.; Dang, C.V.; et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. *Cancer Cell* **2010**, *18*, 207–219. [CrossRef]

232. Wang, G.; Li, Y.; Yang, Z.; Xu, W.; Yang, Y.; Tan, X. ROS mediated EGFR/MEK/ERK/HIF-1α Loop Regulates Glucose metabolism in pancreatic cancer. *Biochem. Biophys. Res. Commun.* **2018**, *500*, 873–878. [CrossRef]

233. Cardoso, M.R.; Santos, J.C.; Ribeiro, M.L.; Talarico, M.C.R.; Viana, L.R.; Derchain, S.F.M. A metabolomic approach to predict breast cancer behavior and chemotherapy response. *Int. J. Mol. Sci.* **2018**, *19*, 617. [CrossRef] [PubMed]

234. Gomes, L.; Viana, L.; Silva, J.L.; Mermelstein, C.; Atella, G.; Fialho, E. Resveratrol Modifies Lipid Composition of Two Cancer Cell Lines. *Biomed Res. Int.* **2020**, *2020*, 1–10. [CrossRef] [PubMed]

235. Ávila-Gálvez, M.A.; García-Villalba, R.; Martínez-Díaz, F.; Ocaña-Castillo, B.; Monedero-Saiz, T.; Torrecillas-Sánchez, A.; Abellán, B.; González-Sarrión, A.; Espín, J.C. Metabolic Profiling of Dietary Polyphenols and Methylxanthines in Normal and Malignant Mammary Tissues from Breast Cancer Patients. *Mol. Nutr. Food Res.* **2019**, *63*, 1801239. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).